SG11201500232UA - Chiral control - Google Patents

Chiral control

Info

Publication number
SG11201500232UA
SG11201500232UA SG11201500232UA SG11201500232UA SG11201500232UA SG 11201500232U A SG11201500232U A SG 11201500232UA SG 11201500232U A SG11201500232U A SG 11201500232UA SG 11201500232U A SG11201500232U A SG 11201500232UA SG 11201500232U A SG11201500232U A SG 11201500232UA
Authority
SG
Singapore
Prior art keywords
chiral control
chiral
control
Prior art date
Application number
SG11201500232UA
Other languages
English (en)
Inventor
David Butler
Naoki Iwamoto
Meena Meena
Nenad Svrzikapa
Gregory L Verdine
Ivan Zlatev
Original Assignee
Wave Life Sciences Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wave Life Sciences Pte Ltd filed Critical Wave Life Sciences Pte Ltd
Publication of SG11201500232UA publication Critical patent/SG11201500232UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/02—Phosphorylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Massaging Devices (AREA)
  • Paper (AREA)
  • Extrusion Moulding Of Plastics Or The Like (AREA)
SG11201500232UA 2012-07-13 2013-07-12 Chiral control SG11201500232UA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261671656P 2012-07-13 2012-07-13
US201261671655P 2012-07-13 2012-07-13
US201261671722P 2012-07-14 2012-07-14
US201261671724P 2012-07-14 2012-07-14
PCT/US2013/050407 WO2014012081A2 (fr) 2012-07-13 2013-07-12 Contrôle chiral

Publications (1)

Publication Number Publication Date
SG11201500232UA true SG11201500232UA (en) 2015-04-29

Family

ID=49916709

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201500232UA SG11201500232UA (en) 2012-07-13 2013-07-12 Chiral control
SG10201912895PA SG10201912895PA (en) 2012-07-13 2013-07-12 Chiral control
SG10201700283WA SG10201700283WA (en) 2012-07-13 2013-07-12 Chiral control

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201912895PA SG10201912895PA (en) 2012-07-13 2013-07-12 Chiral control
SG10201700283WA SG10201700283WA (en) 2012-07-13 2013-07-12 Chiral control

Country Status (17)

Country Link
US (4) US9982257B2 (fr)
EP (2) EP4219516A3 (fr)
JP (3) JP6453212B2 (fr)
KR (4) KR102712879B1 (fr)
CN (2) CN112007045A (fr)
AU (4) AU2013289880B2 (fr)
CA (1) CA2878945A1 (fr)
CL (1) CL2015000092A1 (fr)
DK (1) DK2872147T3 (fr)
ES (1) ES2940887T3 (fr)
HK (1) HK1210595A1 (fr)
IL (1) IL236621B (fr)
MX (1) MX2015000577A (fr)
PL (1) PL2872147T3 (fr)
RU (1) RU2015104762A (fr)
SG (3) SG11201500232UA (fr)
WO (1) WO2014012081A2 (fr)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101881596B1 (ko) 2008-12-02 2018-07-24 웨이브 라이프 사이언시스 재팬 인코포레이티드 인 원자 변형된 핵산의 합성 방법
CN102596204B (zh) 2009-07-06 2016-11-23 波涛生命科学有限公司 新的核酸前药及其使用方法
WO2012039448A1 (fr) 2010-09-24 2012-03-29 株式会社キラルジェン Groupe auxiliaire asymétrique
WO2012068405A2 (fr) 2010-11-17 2012-05-24 Isis Pharmaceuticals, Inc. Modulation de l'expression de l'alpha synucléine
ES2626488T3 (es) * 2011-07-19 2017-07-25 Wave Life Sciences Pte. Ltd. Procedimientos para la síntesis de ácidos nucleicos funcionalizados
CA2866392C (fr) 2012-03-30 2023-10-24 Washington University Procedes de modulation de l'expression de tau pour reduire l'avc et modifier un symptome neurodegeneratif
SG11201500232UA (en) * 2012-07-13 2015-04-29 Wave Life Sciences Pte Ltd Chiral control
AU2013288048A1 (en) 2012-07-13 2015-01-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
EP2873674B1 (fr) 2012-07-13 2020-05-06 Shin Nippon Biomedical Laboratories, Ltd. Adjuvant d'acide nucléique chiral
RU2745324C2 (ru) 2013-03-14 2021-03-23 Ионис Фармасьютикалз, Инк. Композиции и способы модулирования экспрессии tau
TWI772856B (zh) 2013-07-19 2022-08-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
EP3095459A4 (fr) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Adjuvant d'acide nucléique chiral ayant un effet antitumoral et agent antitumoral
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
EP3095461A4 (fr) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Adjuvant d'acide nucléique chiral possédant une activité d'induction d'immunité, et activateur d'induction d'immunité
CN106068325B (zh) * 2014-01-16 2021-07-09 波涛生命科学有限公司 手性设计
WO2015125845A1 (fr) * 2014-02-20 2015-08-27 塩野義製薬株式会社 Modification de site phosphate d'acide nucléique contenant un hétérocycle non aromatique contenant de l'azote
WO2015133522A1 (fr) * 2014-03-04 2015-09-11 国立大学法人大阪大学 Médicament contre le cancer colorectal, et méthode prognostique pour les patients atteints d'un cancer colorectal
US10619156B2 (en) 2014-05-28 2020-04-14 The Regents Of The University Of California Hybrid tRNA/pre-miRNA molecules and methods of use
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
RU2708237C2 (ru) 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения
CN107109411B (zh) 2014-10-03 2022-07-01 冷泉港实验室 核基因输出的定向增加
US20180016575A1 (en) * 2014-11-19 2018-01-18 Roche Innovation Center Copenhagen A/S LNA Gapmer Oligonucleotides Comprising Chiral Phosphorothioate Linkages
JP6689279B2 (ja) * 2014-12-16 2020-05-20 ロシュ イノベーション センター コペンハーゲン エーエス キラル毒性のスクリーニング方法
DK3234134T3 (da) 2014-12-17 2020-07-27 Proqr Therapeutics Ii Bv Målrettet rna-redigering
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
WO2017053781A1 (fr) 2015-09-25 2017-03-30 Ionis Pharmaceuticals, Inc. Compositions et méthodes de modulation de l'expression de l'ataxine 3
IL295755A (en) * 2015-10-09 2022-10-01 Wave Life Sciences Ltd Oligonucleotide preparations and methods thereof
AU2016334804B2 (en) 2015-10-09 2022-03-31 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
CN109312343B (zh) 2015-12-14 2022-09-27 冷泉港实验室 用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体
JP6907939B2 (ja) * 2016-01-28 2021-07-21 東レ株式会社 癌の治療及び／又は予防用医薬組成物
EP3430019A4 (fr) 2016-03-13 2019-10-30 Wave Life Sciences Ltd. Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides
JP7017517B2 (ja) * 2016-03-18 2022-02-08 ロシュ イノベーション センター コペンハーゲン エーエス アシル保護ｌ－ｌｎａ－グアノシンモノマー
MA45471A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques de phosphatidylinositol-3-kinase et leurs utilisations
MA45470A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques kras et leurs utilisations
MA45349A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques egfr et leurs utilisations
MA45469A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques de bêta-caténine et leurs utilisations
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
CA3021267A1 (fr) 2016-04-18 2017-10-26 Sarepta Therapeutics, Inc. Oligomeres antisens et procedes d'utilisation de ceux-ci pour le traitement de maladies associees au gene de l'alpha-glucosidase acide
NZ747685A (en) 2016-04-29 2023-05-26 Sarepta Therapeutics Inc Oligonucleotide analogues targeting human lmna
MA45270A (fr) 2016-05-04 2017-11-09 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
US11261209B2 (en) * 2016-05-12 2022-03-01 Roche Innovation Center Copenhagen A/S Enhanced coupling of stereodefined oxazaphospholidine phosphoramidite monomers to nucleoside or oligonucleotide
EP3458464A1 (fr) * 2016-05-18 2019-03-27 ETH Zurich Synthèse stéréosélective d'oligoribonucléotides de phosphorothioate
EP3463386A4 (fr) * 2016-06-03 2020-03-04 Wave Life Sciences Ltd. Oligonucléotides, compositions et méthodes associées
MA45496A (fr) 2016-06-17 2019-04-24 Hoffmann La Roche Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
WO2017220751A1 (fr) 2016-06-22 2017-12-28 Proqr Therapeutics Ii B.V. Oligonucléotides d'édition d'arn monocaténaire
US20190262375A1 (en) 2016-06-30 2019-08-29 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
CN110023321A (zh) 2016-08-17 2019-07-16 索尔斯蒂斯生物有限公司 多核苷酸构建体
NZ751483A (en) 2016-09-01 2022-07-01 Proqr Therapeutics Ii Bv Chemically modified single-stranded rna-editing oligonucleotides
JOP20190065A1 (ar) * 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن tau
JOP20190104A1 (ar) * 2016-11-10 2019-05-07 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن atxn3
US11873316B2 (en) 2016-11-23 2024-01-16 Wave Life Sciences Ltd. Compositions and methods for phosphoramidite and oligonucleotide synthesis
CA3043768A1 (fr) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes destines a l'administration d'agents therapeutiques
EP3554553B1 (fr) 2016-12-19 2022-07-20 Sarepta Therapeutics, Inc. Conjugués oligomère de sauts d'exons pour la dystrophie musculaire
KR20240006057A (ko) 2016-12-19 2024-01-12 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
ES2980686T3 (es) 2016-12-19 2024-10-02 Sarepta Therapeutics Inc Conjugados de oligómero de omisión de exones para distrofia muscular
CN110381980A (zh) 2017-01-06 2019-10-25 艾维迪提生物科学有限责任公司 核酸-多肽组合物以及诱导外显子跳读的方法
US11274300B2 (en) 2017-01-19 2022-03-15 Proqr Therapeutics Ii B.V. Oligonucleotide complexes for use in RNA editing
EP3603648A4 (fr) 2017-03-29 2020-12-30 Shionogi & Co., Ltd Complexe de médicament d'acide nucléique et de lipide multiramifié
KR20190135494A (ko) 2017-03-29 2019-12-06 로슈 이노베이션 센터 코펜하겐 에이/에스 입체한정된 포스포로티오에이트 올리고뉴클레오티드의 제조를 위한 직교 보호기
US11603532B2 (en) 2017-06-02 2023-03-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
EP3630788A4 (fr) * 2017-06-02 2021-04-28 Wave Life Sciences Ltd. Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3630789A4 (fr) * 2017-06-02 2021-06-16 Wave Life Sciences Ltd. Compositions d'oligonucléotides et leurs procédés d'utilisation
CN111051281A (zh) * 2017-06-21 2020-04-21 波涛生命科学有限公司 用于合成的化合物、组合物和方法
CN110831951B (zh) * 2017-06-28 2023-10-27 罗氏创新中心哥本哈根有限公司 多重偶联和氧化方法
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
US20200362337A1 (en) * 2017-08-08 2020-11-19 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
SI3673080T1 (sl) 2017-08-25 2024-03-29 Stoke Therapeutics, Inc. Protismiselni oligomeri za zdravljenje bolezenskih stanj in bolezni
AU2018333065B2 (en) * 2017-09-18 2024-04-18 Wave Life Sciences Ltd. Technologies for oligonucleotide preparation
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
US20200248178A1 (en) 2017-09-28 2020-08-06 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
JP2020536058A (ja) 2017-09-28 2020-12-10 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーを処置するための併用療法
JP2020536057A (ja) 2017-09-28 2020-12-10 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーを処置するための併用療法
EP3691657A4 (fr) 2017-10-04 2021-07-21 Avidity Biosciences, Inc. Compositions d'acide nucléique-polypeptide et utilisations de celles-ci
US11596646B2 (en) 2017-10-12 2023-03-07 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
KR20200030594A (ko) 2017-10-16 2020-03-20 에프. 호프만-라 로슈 아게 B형 간염 감염을 치료하기 위한 PAPD5 및 PAPD7 mRNA의 감소용 핵산 분자
JP7394753B2 (ja) 2017-10-18 2023-12-08 サレプタ セラピューティクス， インコーポレイテッド アンチセンスオリゴマー化合物
TWI809004B (zh) * 2017-11-09 2023-07-21 美商Ionis製藥公司 用於降低snca表現之化合物及方法
AU2018363837A1 (en) * 2017-11-13 2020-05-28 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages
EP4328306A2 (fr) 2017-12-01 2024-02-28 The Texas A&M University System Traitement antisens du syndrome d'angelman
MX2020005860A (es) 2017-12-06 2020-09-09 Avidity Biosciences Inc Composiciones y metodos de tratamiento de atrofia muscular y distrofia miotonica.
CN108186564B (zh) * 2018-01-03 2020-06-02 上海市肿瘤研究所 一种肿瘤微环境响应型基因纳米胶束及其制备方法和应用
WO2019152919A2 (fr) * 2018-02-04 2019-08-08 The Texas A&M University System Systèmes et procédés de déplacement de brins d'acide nucléique hétérochiraux
JP2021516673A (ja) * 2018-03-14 2021-07-08 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｌｎａ−ジカルボン酸誘導体およびその調製のための方法
IL277889B1 (en) * 2018-04-12 2024-09-01 Wave Life Sciences Ltd Preparations of oligonucleotides and methods of using them
US12060558B2 (en) 2018-05-04 2024-08-13 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
KR20210018267A (ko) 2018-05-07 2021-02-17 알닐람 파마슈티칼스 인코포레이티드 간외 전달
BR112020021253A2 (pt) 2018-05-09 2021-02-02 Ionis Pharmaceuticals, Inc. compostos e métodos para redução da expressão de atxn3
US10765760B2 (en) 2018-05-29 2020-09-08 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
EP4219717A3 (fr) 2018-06-13 2023-12-20 Sarepta Therapeutics, Inc. Oligomères à saut d'exon pour la dystrophie musculaire
CR20210058A (es) 2018-07-03 2021-03-22 Hoffmann La Roche Oligonucleótidos para modular la expresión de tau
TW202020153A (zh) 2018-07-27 2020-06-01 美商薩羅塔治療公司 用於肌肉萎縮症之外顯子跳躍寡聚物
AU2019392928A1 (en) * 2018-12-06 2021-06-17 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
CN113412330A (zh) 2018-12-13 2021-09-17 萨勒普塔医疗公司 用于肌营养不良的外显子跳跃寡聚物缀合物
SG11202106593UA (en) 2018-12-21 2021-07-29 Avidity Biosciences Inc Anti-transferrin receptor antibodies and uses thereof
CN109837326B (zh) * 2019-01-17 2022-07-05 嘉兴学院 基于多价捕获并放大输出信号的生物靶标分子检测方法
CN113498491B (zh) * 2019-02-27 2024-09-17 日产化学株式会社 树脂组合物、树脂膜以及液晶显示元件
WO2020191252A1 (fr) * 2019-03-20 2020-09-24 Wave Life Sciences Ltd. Technologies utiles pour la préparation d'oligonucléotides
SG11202110180TA (en) * 2019-03-26 2021-10-28 Rutgers The State University Of New Jersey Compositions and methods for treating neurodegenerative disorders
WO2020214763A1 (fr) 2019-04-18 2020-10-22 Sarepta Therapeutics, Inc. Compositions pour le traitement de la dystrophie musculaire
EP3972983A4 (fr) * 2019-05-17 2023-05-24 Ionis Pharmaceuticals, Inc. Synthèse de composés oligomères comprenant des liaisons diester de phosphorothioate et diester de phosphate
CN110346493B (zh) * 2019-05-23 2021-01-05 中国人民解放军军事科学院军事医学研究院 检测猕猴血浆中中期因子反义寡核苷酸含量的方法
US12006499B2 (en) 2019-06-06 2024-06-11 Avidity Biosciences, Inc. Una amidites and uses thereof
WO2020247782A1 (fr) 2019-06-06 2020-12-10 Avidity Biosciences, Inc. Compositions d'acide nucléique-polypeptide et utilisations de celles-ci
JP2023537798A (ja) 2020-03-19 2023-09-06 アビディティー バイオサイエンシーズ，インク． 顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法
US11446387B2 (en) 2020-03-27 2022-09-20 Avidity Biosciences, Inc. Compositions and methods of treating muscle dystrophy
IL298063A (en) 2020-05-11 2023-01-01 Stoke Therapeutics Inc opa1 antisense oligomers for the treatment of conditions and diseases
IL298406A (en) 2020-05-22 2023-01-01 Wave Life Sciences Ltd Double-stranded oligonucleotide assemblies and related methods
CN112063608B (zh) * 2020-08-27 2022-06-17 浙江工业大学 一种脂肪酸光脱羧酶突变体及其在l-草铵膦合成中的应用
KR20240055874A (ko) 2021-09-16 2024-04-29 어비디티 바이오사이언시스 인크. 안면견갑상완 근이영양증을 치료하는 조성물 및 방법
EP4392558A1 (fr) 2021-09-30 2024-07-03 Sarepta Therapeutics, Inc. Oligonucléotides antisens ayant une ou plusieurs unités abasiques
CN114230498B (zh) * 2021-12-30 2023-11-17 湖北华世通生物医药科技有限公司 β-(二甲氨基)乙基对甲苯磺酸巯酯盐酸盐的制备方法
CN115181736B (zh) * 2022-01-07 2023-05-30 中国科学院海洋研究所 一种可以结合脂多糖的蛋白酶pck及其制备和应用
WO2023152371A1 (fr) 2022-02-14 2023-08-17 Proqr Therapeutics Ii B.V. Oligonucléotides guides pour l'édition d'acides nucléiques dans le traitement de l'hypercholestérolémie
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
WO2024013360A1 (fr) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Oligonucléotides chimiquement modifiés pour édition d'arn médiée par adar
WO2024013361A1 (fr) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Oligonucléotides pour édition d'arn médiée par adar et leur utilisation
WO2024064237A2 (fr) 2022-09-21 2024-03-28 Sarepta Therapeutics, Inc. Efficacité du saut d'exon médié par un oligonucléotide antisens dans le traitement de la dmd
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
WO2024097310A2 (fr) * 2022-11-01 2024-05-10 Impilo Therapeutics, Inc. Administration ciblée d'acide nucléique non chargé (ncna) et nanocomplexes de pénétration tumorale associés
WO2024110565A1 (fr) 2022-11-24 2024-05-30 Proqr Therapeutics Ii B.V. Oligonucléotides antisens pour le traitement de l'hémochromatose hfe héréditaire
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
WO2024121373A1 (fr) 2022-12-09 2024-06-13 Proqr Therapeutics Ii B.V. Oligonucléotides antisens pour le traitement d'une maladie cardiovasculaire
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
WO2024175550A1 (fr) 2023-02-20 2024-08-29 Proqr Therapeutics Ii B.V. Oligonucléotides antisens pour le traitement d'une maladie cardiovasculaire athérosclérotique
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
WO2024206175A1 (fr) 2023-03-24 2024-10-03 Proqr Therapeutics Ii B.V. Oligonucléotides antisens pour le traitement de troubles neurologiques
WO2024200472A1 (fr) 2023-03-27 2024-10-03 Proqr Therapeutics Ii B.V. Oligonucléotides antisens pour traitement des maladies du foie

Family Cites Families (651)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE133885C (fr)
US513030A (en) 1894-01-16 Machine for waxing or coating paper
US2878264A (en) 1959-03-17 Substituted amino alcohols
DE1144279B (de) 1957-09-26 1963-02-28 Robins Co Inc A H Verfahren zur Herstellung von 3-Aryl-3-hydroxypyrrolidinen und deren Salzen
US3135766A (en) 1961-10-03 1964-06-02 Mead Johnson & Co 3-substituted-3-pyrrolidinols
US3484473A (en) 1967-05-12 1969-12-16 Buckman Labor Inc Methylene bisesters of thiolsulfonic acids
DE1934150A1 (de) 1968-07-10 1970-01-15 Pennwalt Corp Neue 1-Alkanoyloxy-1,2,4,5-tetrahydro-3H,3-benzazepine
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US3745162A (en) 1970-08-31 1973-07-10 Robins Co Inc A H 1,2,3,4-tetrahydroisoquinoline-2-(thio)-carboxamides
GB1448437A (en) 1973-02-24 1976-09-08 Beecham Group Ltd Diphenylpropylamines
US4022791A (en) 1975-06-03 1977-05-10 Pfizer Inc. 2-Aminomethyl-3,4-dihydronaphthalenes
GB1504424A (en) 1975-08-09 1978-03-22 Beecham Group Ltd Isoquinoline-derived aminoethers
BR7807288A (pt) 1977-11-08 1979-06-12 Genentech Inc Processo para sintese de polinucleotidos
DD133885B1 (de) 1978-01-04 1981-02-25 Hans Lehmann Mittel zur bekaempfung von phytopathogenen bakterien und pilzen
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4542142A (en) 1982-11-22 1985-09-17 Roussel Uclaf Insecticidal cyclopropane carboxylic acid derivatives with 3-unsaturated-side chain
USRE34069E (en) 1983-08-18 1992-09-15 Biosyntech Gmbh Process for the preparation of oligonucleotides
DE3329892A1 (de) 1983-08-18 1985-03-07 Köster, Hubert, Prof. Dr., 2000 Hamburg Verfahren zur herstellung von oligonucleotiden
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5643889A (en) 1984-07-11 1997-07-01 Temple University-Of The Commonwealth System Of Pennsylvania Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
FR2576898B1 (fr) 1985-02-01 1988-01-08 Lafon Labor Derives de 3-phenyl-tetrahydropyridine, procede de preparation et utilisation en therapeutique
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
US4735949A (en) 1986-02-18 1988-04-05 Warner-Lambert Company Disubstituted-7-pyrrolidinonaphthyridine antibacterial agents
US4840956A (en) 1986-02-18 1989-06-20 Warner-Lambert Company Novel disubstituted-7-pyrrolidinoquinoline antibacterial agents
IL83663A0 (en) 1986-10-27 1988-01-31 Robins Co Inc A H Preparation of 3-pyrrolidinols
WO1988010264A1 (fr) 1987-06-24 1988-12-29 Howard Florey Institute Of Experimental Physiology Derives de nucleosides
US5200553A (en) 1987-07-30 1993-04-06 Kupat Holim Health Insurance Institution Of The General Federation Of Labor Biologically active carboxylic acid esters
US4923901A (en) 1987-09-04 1990-05-08 Millipore Corporation Membranes with bound oligonucleotides and peptides
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
JP2794461B2 (ja) 1989-08-17 1998-09-03 有機合成薬品工業株式会社 ホスホアミダイト化合物及びそれを用いたオリゴリボヌクレオチドの固相合成法
US5141813A (en) 1989-08-28 1992-08-25 Clontech Laboratories, Inc. Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
CA2029273A1 (fr) 1989-12-04 1991-06-05 Christine L. Brakel Compose a base de nucleotide modifie
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
EP0507863A4 (en) 1989-12-28 1993-07-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
US5620963A (en) 1991-10-15 1997-04-15 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5914396A (en) 1990-01-11 1999-06-22 Isis Pharmaceuticals, Inc. 2'-O-modified nucleosides and phosphoramidites
US5635488A (en) 1991-10-15 1997-06-03 Isis Pharmaceuticals, Inc. Compounds having phosphorodithioate linkages of high chiral purity
US5852188A (en) 1990-01-11 1998-12-22 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5212295A (en) 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
CA2073500C (fr) 1990-01-11 2008-03-25 Phillip Dan Cook Compositions et methodes pour deceler et moduler l'activite de l'arn et l'expression genique
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
WO1993013121A1 (fr) 1991-12-24 1993-07-08 Isis Pharmaceuticals, Inc. Oligonucleotides modifies en 2', a ouverture
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US6339066B1 (en) 1990-01-11 2002-01-15 Isis Pharmaceuticals, Inc. Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
US5506212A (en) 1990-01-11 1996-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides with substantially chirally pure phosphorothioate linkages
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5292875A (en) 1990-04-20 1994-03-08 Lynx Therapeutics, Inc. Method of synthesizing sulfurized oligonucleotide analogs
WO1991017755A1 (fr) 1990-05-23 1991-11-28 Isis Pharmaceuticals, Inc. Compositions et procedes servant a moduler l'activite de l'arn par modification de la structure 5' cap de l'arn
US5587468A (en) 1990-06-11 1996-12-24 University Research Corporation High affinity nucleic acid ligands to HIV integrase
US5654151A (en) 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5780228A (en) 1990-06-11 1998-07-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5668264A (en) 1990-06-11 1997-09-16 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US5861254A (en) 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5869641A (en) 1990-06-11 1999-02-09 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of CD4
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5726017A (en) 1990-06-11 1998-03-10 Nexstar Pharmaceuticals, Inc. High affinity HIV-1 gag nucleic acid ligands
US5846713A (en) 1990-06-11 1998-12-08 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5543293A (en) 1990-06-11 1996-08-06 Nexstar Pharmaceuticals, Inc. DNA ligands of thrombin
US6331394B1 (en) 1991-06-10 2001-12-18 Gilead Sciences, Inc. Nucleic acid ligands to integrins
US6232071B1 (en) 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US6261774B1 (en) 1990-06-11 2001-07-17 Gilead Sciences, Inc. Truncation selex method
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5527894A (en) 1990-06-11 1996-06-18 Nexstar Pharmacueticals, Inc. Ligands of HIV-1 tat protein
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
DE69126530T2 (de) 1990-07-27 1998-02-05 Isis Pharmaceutical, Inc., Carlsbad, Calif. Nuklease resistente, pyrimidin modifizierte oligonukleotide, die die gen-expression detektieren und modulieren
US5610289A (en) * 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5512668A (en) 1991-03-06 1996-04-30 Polish Academy Of Sciences Solid phase oligonucleotide synthesis using phospholane intermediates
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
JPH04348077A (ja) 1991-05-24 1992-12-03 Nec Corp 薄膜トランジスタ
US6414112B1 (en) 1991-05-24 2002-07-02 Ole Buchardt Peptide nucleic acids having 2,6-diaminopurine nucleobases
WO1992022655A1 (fr) 1991-06-10 1992-12-23 Lucky Limited Diagnostics de l'hepatite c et vaccin anti-hepatite c
US5359052A (en) 1991-08-05 1994-10-25 Polish Academy Of Sciences Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
US5646267A (en) 1991-08-05 1997-07-08 Polish Academy Of Sciences Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
US7119184B2 (en) 1991-08-12 2006-10-10 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US6369209B1 (en) 1999-05-03 2002-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US5661134A (en) 1991-10-15 1997-08-26 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
EP0655088B1 (fr) 1991-10-15 2002-07-24 Isis Pharmaceuticals, Inc. Oligonucleotides presentant des liaisons phosphorees chirales
US5607923A (en) 1991-10-15 1997-03-04 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
US5576302A (en) 1991-10-15 1996-11-19 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
US5599797A (en) 1991-10-15 1997-02-04 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5654284A (en) 1991-10-15 1997-08-05 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
DE59208572D1 (de) 1991-10-17 1997-07-10 Ciba Geigy Ag Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
CA2135646A1 (fr) 1992-05-11 1993-11-25 Kenneth G. Draper Methode et reagent permettant l'inhibition de la replication virale
GB9213601D0 (en) 1992-06-26 1992-08-12 Mastico Robert A Protein based delivery system
EP1251170A3 (fr) 1992-07-17 2002-10-30 Ribozyme Pharmaceuticals, Inc. Procédé et réactif pour le traitement de maladies animales dépendants de NF-kappaB
US7067497B2 (en) 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
ES2086997T3 (es) 1993-01-25 1996-07-01 Hybridon Inc Oligonucleotido-alquilfosfonatos y -alquilfosfonotioatos.
WO1994022890A1 (fr) 1993-03-31 1994-10-13 Sterling Winthop Inc. Nouveaux nucleosides substitues en position 5' et oligomeres obtenus a partir de ceux-ci
US5955591A (en) 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
US6015886A (en) 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
DE69412704T2 (de) 1993-06-10 1999-02-04 Idemitsu Petrochemical Co., Ltd., Tokio/Tokyo Spritzgiessform
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
EP0732929B1 (fr) 1993-10-29 2008-05-14 The Brigham And Women's Hospital, Inc. Utilisation therapeutique de leurres d'elements cis in vivo
US5643989A (en) 1993-10-29 1997-07-01 Azdel, Inc. Fiber reinforced functionalized polyolefin composites
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
DE4435728A1 (de) 1994-01-19 1995-07-20 Boehringer Mannheim Gmbh Biotinsilan-Verbindungen und diese Verbindungen enthaltende Bindematrix
WO1995021853A1 (fr) 1994-02-10 1995-08-17 Nexstar Pharmaceuticals, Inc. Ligands a forte affinite avec le facteur de croissance fibroblaste basique et la thrombine
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
ATE222604T1 (de) 1994-02-22 2002-09-15 Novozymes As Methode zur herstellung einer variante eines lipolytischen enzymes
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
EP0759073A1 (fr) 1994-05-11 1997-02-26 Novo Nordisk A/S ENZYME PRESENTANT UNE ACTIVITE D'ENDO-1,3(4)-$g(b)-GLUCANASE
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
AU3675195A (en) 1994-09-07 1996-03-27 Hybridon, Inc. Oligonucleotide prodrugs
US5681940A (en) 1994-11-02 1997-10-28 Icn Pharmaceuticals Sugar modified nucleosides and oligonucleotides
JPH10511267A (ja) 1994-12-22 1998-11-04 ハイブリドン・インコーポレイテッド 立体特異的なオリゴヌクレオチドホスホロチオエートの合成
GB9501465D0 (en) 1995-01-25 1995-03-15 King S College London Nucleoside phosphorothioate derivatives,synthesis and use thereof
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
AU5301996A (en) 1995-03-06 1996-09-23 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to secretory phospholipase a2(spla2)
AU5359496A (en) 1995-03-06 1996-09-23 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
DE69638104D1 (de) 1995-04-27 2010-02-11 Takara Bio Inc Für Lacto-N-biosidase kodierendes Gen
DK0824588T3 (da) 1995-05-11 2004-08-16 Applied Research Systems Inhibitor af IL-6 aktivitet
WO1996037504A1 (fr) 1995-05-23 1996-11-28 Hybridon, Inc. Synthons d'un type nouveau permettant la synthese stereoselective d'oligonucleotides
AU5871196A (en) 1995-05-23 1996-12-24 Hybridon, Inc. Methods and compounds for the synthesis of oligonucleotides and the oligonucleotides thereby produced
EP0831854A4 (fr) 1995-06-06 2001-01-24 Isis Pharmaceuticals Inc Oligonucleotides de grande purete chirale ayant des liaisons phosphorothioate
US5932450A (en) 1995-06-07 1999-08-03 Gen-Probe Incorporated Enzymatic synthesis of oligonucleotides using digestible templates
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
US6111095A (en) 1995-06-07 2000-08-29 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
EP0759470B1 (fr) 1995-06-29 2006-10-25 Takara Bio Inc. Gene codant pour un activateur de l'endoglycoceramidase
US5795765A (en) 1995-06-29 1998-08-18 Takara Shuzo Co., Ltd. Gene encoding endoglycoceramidase
US6017700A (en) 1995-08-04 2000-01-25 Bayer Corporation Cationic oligonucleotides, and related methods of synthesis and use
US5936080A (en) 1996-05-24 1999-08-10 Genta Incorporated Compositions and methods for the synthesis of organophosphorus derivatives
WO1997009443A1 (fr) 1995-09-05 1997-03-13 Michigan State University Procede d'isolement et de purification du taxol et des taxanes a partir du taxus spp
US5734041A (en) 1995-10-20 1998-03-31 Mcgill University Preparation of chiral phosphorothioate oligomers
US6476216B1 (en) 1995-10-20 2002-11-05 Mcgill University Preparation of phosphorothioate oligomers
US6160109A (en) 1995-10-20 2000-12-12 Isis Pharmaceuticals, Inc. Preparation of phosphorothioate and boranophosphate oligomers
US5856085A (en) 1995-12-01 1999-01-05 The Penn State Research Foundation Compositions and methods of developing oligonucleotides and oligonucleotide analogs having antiviral activity
US7018793B1 (en) 1995-12-07 2006-03-28 Diversa Corporation Combinatorial screening of mixed populations of organisms
ATE468396T1 (de) 1996-02-01 2010-06-15 Gilead Sciences Inc Nukleinsäureliganden mit hoher affinität für das c1q protein des komplementsystems
JP2000506384A (ja) 1996-02-15 2000-05-30 ナショナル インスティチューツ オブ ヘルス ＲＮａｓｅ Ｌ アクチベーター及びＲＳＶ感染の治療に有効なアンチセンスオリゴヌクレオチド
US6214805B1 (en) 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
GB9604669D0 (en) 1996-03-05 1996-05-01 Ciba Geigy Ag Chemical compounds
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
DK0898618T3 (da) 1996-05-10 2008-02-25 Novozymes As Fremgangsmåde til tilvejebringelse af hidtil ukendte DNA-sekvenser
US5856465A (en) 1996-05-24 1999-01-05 Polska Akademia Nauk Centrum Badan Molekularnych I Makromolekularnych Compositions and methods for the synthesis of chirally pure organophosphorus nucleoside derivatives
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
DE19622783A1 (de) 1996-06-07 1997-12-11 Hoechst Ag Isolierung der Biosynthesegene für Pseudo-Oligosaccharide aus Streptomyces glaucescens GLA.O und ihre Verwendung
ATE339514T1 (de) 1996-07-16 2006-10-15 Gen Probe Inc Verfahren zum nachweis und amplifikation von nukleinsäuresequenzen unter verbrauch von modifizierten oligonukleotiden mit erhöhter zielschmelztemperatur (tm)
CA2261566A1 (fr) 1996-07-24 1998-01-29 Buchardt, Dorte Acides nucleiques peptidiques presentant une affinite de fixation, une specificite de sequence et une solubilite accrues
AU4156197A (en) 1996-08-21 1998-03-06 Hybridon, Inc. Oligonucleotide prodrugs
AU4161997A (en) 1996-08-30 1998-03-19 Hybridon, Inc. Novel sulfur transfer reagents for oligonucleotide synthesis
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
BR9714438A (pt) 1996-12-27 2000-03-21 Inc Pharmaceuticals Inc Oligoaptâmeros ricos em g e métodos de modulação de uma resposta imune
US6172209B1 (en) 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
US6639062B2 (en) 1997-02-14 2003-10-28 Isis Pharmaceuticals, Inc. Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
US6369237B1 (en) 1997-03-07 2002-04-09 President And Fellows Of Harvard College DNA glycosylase inhibitors, and uses related thereto
US6015887A (en) 1997-04-11 2000-01-18 Isis Pharmaceuticals, Inc. Chiral peptide nucleic acids and methods for preparing same
US6468983B2 (en) 1997-04-21 2002-10-22 The Cleveland Clinic Foundation RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
PL184612B1 (pl) 1997-04-25 2002-11-29 Pan Sposób wytwarzania modyfikowanych P chiralnych analogów nukleotydów
CA2291839A1 (fr) 1997-05-28 1998-12-03 Peter E. Nielsen Acides nucleiques peptidiques conjugues presentant une fixation cellulaire accrue
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO1999005160A2 (fr) 1997-07-25 1999-02-04 Hybridon, Inc. Oligonucleotides possedant des thiophosphates stereospecifiques aux extremites 3'
GB9717158D0 (en) 1997-08-13 1997-10-22 King S College London Solution synthesis of oligonucleotides and their phosphorothioate analogues
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6767739B2 (en) 2001-07-30 2004-07-27 Isis Pharmaceuticals Inc. Antisense modulation of microsomal triglyceride transfer protein expression
US6750344B1 (en) 1997-09-05 2004-06-15 Isis Pharmaceuticals, Inc. Amine compounds and combinatorial libraries comprising same
DE19741715A1 (de) 1997-09-22 1999-03-25 Hoechst Ag Pentopyranosyl-Nucleosid, seine Herstellung und Verwendung
US6528640B1 (en) 1997-11-05 2003-03-04 Ribozyme Pharmaceuticals, Incorporated Synthetic ribonucleic acids with RNAse activity
US6617438B1 (en) 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US6080543A (en) 1997-12-08 2000-06-27 E. & J. Gallo Winery Detection of fungal pathogens
US6582936B1 (en) 1997-12-12 2003-06-24 The Regents Of The University Of California Methods for making nucleic acids
US6248519B1 (en) 1998-03-11 2001-06-19 E & J Gallo Winery Detection of fermentation-related microorganisms
US7045610B2 (en) 1998-04-03 2006-05-16 Epoch Biosciences, Inc. Modified oligonucleotides for mismatch discrimination
WO1999056755A1 (fr) 1998-05-06 1999-11-11 University Of Iowa Research Foundation Methodes de prevention et de traitement des parasitoses et maladies associees a l'aide d'oligonucleotides cpg
NZ508650A (en) 1998-05-14 2003-05-30 Coley Pharm Gmbh Regulating hematopoiesis using unmethylated C and G CpG-oligonucleotides with a phosphorothioate modification
US6242589B1 (en) 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
CA2333854A1 (fr) 1998-07-27 2000-02-10 University Of Iowa Research Foundation Stereo-isomeres d'oligonucleotides de type cpg et procedes connexes
WO2000009159A1 (fr) 1998-08-10 2000-02-24 Aquila Biopharmaceuticals, Inc. Compositions de cpg et d'adjuvants a base de saponine et leurs procedes d'utilisation
EP1026243B1 (fr) 1998-08-14 2006-02-01 Japan Science and Technology Agency Acide nucleique capable de se lier specifiquement a une proteine cible ras
WO2000023444A1 (fr) 1998-10-21 2000-04-27 Abbott Laboratories Composes de 4-aminopyrido[2,3-d]pyrimidine a disubstitution 5,7
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
US6423493B1 (en) 1998-10-26 2002-07-23 Board Of Regents The University Of Texas System Combinatorial selection of oligonucleotide aptamers
US6451524B1 (en) 1998-11-25 2002-09-17 Isis Pharmaceuticals, Inc. Identification of disease predictive nucleic acids
AU1742600A (en) 1998-11-25 2000-06-13 Isis Pharmaceuticals, Inc. Identification of disease predictive nucleic acids
DK1141335T3 (da) 1998-12-21 2009-11-09 Genencor Int Kemisk modificerede enzymer med multipelt ladede varianter
WO2000040749A2 (fr) 1999-01-06 2000-07-13 Genenews Inc. Technique de detection de transcrits geniques dans le sang et leur utilisation
US6265172B1 (en) 1999-02-08 2001-07-24 University Of Kentucky Diagnostic test and therapy for manganese superoxide dismutate (mNsod) associated diseases
US6121437A (en) 1999-03-16 2000-09-19 Isis Pharmaceuticals, Inc. Phosphate and thiophosphate protecting groups
US6506594B1 (en) 1999-03-19 2003-01-14 Cornell Res Foundation Inc Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
GB9907245D0 (en) 1999-03-29 1999-05-26 Goldsborough Andrew Cleavage of nucleic acids from solid supports
JP3072345B1 (ja) 1999-03-31 2000-07-31 農林水産省家畜衛生試験場長 豚丹毒菌の組換えサブユニットワクチン
DE19916417A1 (de) 1999-04-01 2000-10-19 Schering Ag Amyloidspezifisches Aptamer
EP1181304B1 (fr) 1999-04-08 2007-10-10 Antisoma Research Limited Procede inhibant la proliferation d'oligonucleotides riches en guanosine et procede de liaison desdits oligonucleotides a la nucleoline
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6300069B1 (en) 1999-05-03 2001-10-09 Qiagen Gmbh Generation and amplification of nucleic acids from ribonucleic acids
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
US6066500A (en) 1999-06-25 2000-05-23 Isis Pharmaceuticals Inc. Antisense modulation of Beta catenin expression
US6271004B1 (en) 1999-06-25 2001-08-07 Display Systems Biotech A/S Method for improved reverse transcription at high temperatures
US6569630B1 (en) 1999-07-02 2003-05-27 Conceptual Mindworks, Inc. Methods and compositions for aptamers against anthrax
US6414135B1 (en) 1999-07-07 2002-07-02 Isis Pharmaceuticals, Inc. C3′-methylene hydrogen phosphonate monomers and related compounds
US20030092647A1 (en) 2001-08-08 2003-05-15 Crooke Rosanne M. Antisense modulation of cholesteryl ester transfer protein expression
DE19935756A1 (de) 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
US6171795B1 (en) 1999-07-29 2001-01-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to CD40ligand
US6147200A (en) 1999-08-19 2000-11-14 Isis Pharmaceuticals, Inc. 2'-O-acetamido modified monomers and oligomers
US7264932B2 (en) 1999-09-24 2007-09-04 Applera Corporation Nuclease inhibitor cocktail
OA12028A (en) 1999-09-25 2006-04-28 Univ Iowa Res Found Immunostimulatory nucleic acids.
ES2265980T5 (es) 1999-09-27 2010-12-28 Coley Pharmaceutical Group, Inc. Metodos relacionados con interferón inducido por ácidos nucleicos inmunoestimuladores.
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US20020082227A1 (en) 1999-09-30 2002-06-27 Scott Henry Use of oligonucleotides for inhibition of complement activation
US6528262B1 (en) 1999-10-06 2003-03-04 Quark Biotech, Inc. Method for enrichment of natural antisense messenger RNA
JP3463098B2 (ja) 1999-10-08 2003-11-05 独立行政法人産業技術総合研究所 モジュレートアプタマー及びこれを用いた標的タンパク質の検出方法
GB9924285D0 (en) 1999-10-14 1999-12-15 Avecia Ltd Process
US20010055761A1 (en) 1999-10-29 2001-12-27 Agilent Technologies Small scale dna synthesis using polymeric solid support with functionalized regions
FR2800750B1 (fr) 1999-11-05 2003-01-31 Centre Nat Rech Scient Proteines membranaires ctl (choline transporter like) impliquees dans le transport de la choline
WO2001040515A1 (fr) 1999-11-12 2001-06-07 Isis Pharmaceuticals, Inc. Oligomeres a espacement possedant des liaisons internucleosidiques phosphorothioate a sites specifiques chiraux
US6322985B1 (en) 1999-12-27 2001-11-27 Technion Research And Development Foundation Ltd. Abundant, well distributed and hyperpolymorphic simple sequence repeats in prokaryote genomes and use of same for prokaryote classification and typing
WO2001050117A1 (fr) 1999-12-30 2001-07-12 Cabot Corporation Capteurs a proprietes ameliorees
WO2001050349A1 (fr) 1999-12-30 2001-07-12 Rutgers, The State University Of New Jersey Personnalisation et transformation de document electronique utilisant un retour d'informations utilisateur
US6649750B1 (en) 2000-01-05 2003-11-18 Isis Pharmaceuticals, Inc. Process for the preparation of oligonucleotide compounds
US6159697A (en) 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
GB0004889D0 (en) 2000-03-01 2000-04-19 Avecia Ltd Synthesis of oligonucleotides
CA2335389A1 (fr) 2000-03-01 2001-09-01 Message Pharmaceuticals, Inc. Nouvelles proteines bacteriennes de rnase p et leur emploi pour l'identification de composes antibacteriens
EP1265840A2 (fr) 2000-03-17 2002-12-18 Corixa Corporation Nouveaux aldehydes amphipathiques et leur utilisation en tant qu'adjuvants et effecteurs immunologiques
DE10019756A1 (de) 2000-04-20 2001-10-25 Bayer Ag Verfahren zur Herstellung von superabsorbierenden Polymeren aus Polyacrylnitrilen
MXPA02010261A (es) 2000-04-20 2003-04-25 Hoffmann La Roche Derivados de pirrolidina y piperidina y su uso para el tratamiento de transtornos neurodegenerativos.
AU2001259706A1 (en) 2000-05-09 2001-11-20 Reliable Biopharmaceutical, Inc. Polymeric compounds useful as prodrugs
US6492171B2 (en) 2000-05-16 2002-12-10 Isis Pharmaceuticals, Inc. Antisense modulation of TERT expression
US6725412B1 (en) 2000-08-15 2004-04-20 Dolby Laboratories Licensing Corporation Low latency data encoder
US6809195B1 (en) 2000-08-16 2004-10-26 Isis Pharmaceuticals, Inc. Process for the preparation of oligonucleotides
US6559279B1 (en) 2000-09-08 2003-05-06 Isis Pharmaceuticals, Inc. Process for preparing peptide derivatized oligomeric compounds
EP1191097A1 (fr) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction du "exon-skipping" dans des cellules eukaryotes
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
WO2002026932A2 (fr) 2000-09-26 2002-04-04 Duke University Aptameres d'arn et procede d'identification desdits aptameres
GB0024752D0 (en) 2000-10-10 2000-11-22 Univ Belfast Oxidative halogenation of aromatic compounds
WO2002033116A2 (fr) 2000-10-16 2002-04-25 Gilead Sciences, Inc. Ligands d'acides nucleiques de l'antigene membranaire prostatique specifique
CA2425358C (fr) 2000-10-18 2012-08-21 Glaxosmithkline Biologicals S.A. Composition vaccinale comprenant qs21, mpl, un oligonucleotide cpg et un antigene du cancer
US6682889B1 (en) 2000-11-08 2004-01-27 Becton, Dickinson And Company Amplification and detection of organisms of the Chlamydiaceae family
JP2002165594A (ja) 2000-11-29 2002-06-11 National Institute Of Advanced Industrial & Technology Ｃ型肝炎ウイルスのｉｒｅｓ及びｎｓ３プロテアーゼを標的とするｒｎａ分子
NL1016978C2 (nl) 2000-12-22 2002-06-25 Robert Jan Colenbrander Inrichting en werkwijze voor het verpakken en bereiden van voedsel en werkwijze voor het vervaardigen van een dergelijke inrichting.
CA2434386C (fr) 2001-01-22 2006-12-05 Merck & Co., Inc. Derives de nucleoside servant d'inhibiteurs de l'arn polymerase virale arn dependante
DK1356037T3 (da) 2001-01-25 2011-06-27 Evolva Ltd Bibliotek med en samling af celler
US8008459B2 (en) 2001-01-25 2011-08-30 Evolva Sa Concatemers of differentially expressed multiple genes
CA2429397C (fr) 2001-01-26 2014-06-03 Commonwealth Scientific And Industrial Research Organisation Procedes et moyens d'elaboration par clonage recombinatoire d'un produit de recombinaison permettant une attenuation transcriptionnelle efficace
CA2442092A1 (fr) 2001-03-26 2002-10-17 Ribozyme Pharmaceuticals, Inc. Inhibition regulee par des oligonucleotides de la replication du virus de l'hepatite b et du virus de l'hepatite c
US20050277133A1 (en) 2001-05-18 2005-12-15 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20030207804A1 (en) 2001-05-25 2003-11-06 Muthiah Manoharan Modified peptide nucleic acids
GB0113523D0 (en) 2001-06-04 2001-07-25 Torotrak Dev Ltd An Hydraulic control circuit for a continuosly variable transmission
US20030069410A1 (en) 2001-06-14 2003-04-10 Isis Pharmaceuticals, Inc. Methods for preparing oligonucleotides having chiral phosphorothioate linkages
CA2451739A1 (fr) 2001-06-29 2003-01-09 Chiron Corporation Compositions de vaccin vhc e1e2
CA2452458A1 (fr) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Oligonucleotides chimeres resistants a la nuclease
US7205399B1 (en) 2001-07-06 2007-04-17 Sirna Therapeutics, Inc. Methods and reagents for oligonucleotide synthesis
US6440739B1 (en) 2001-07-17 2002-08-27 Isis Pharmaceuticals, Inc. Antisense modulation of glioma-associated oncogene-2 expression
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7888324B2 (en) 2001-08-01 2011-02-15 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US6455308B1 (en) 2001-08-01 2002-09-24 Isis Pharmaceuticals, Inc. Antisense modulation of serum amyloid A4 expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en) 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
AU2002361468A1 (en) 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
US20030232978A1 (en) 2001-08-24 2003-12-18 Seeberger Peter H. Reagents that facilitate the purification of compounds synthesized on a solid support
US7049122B2 (en) 2001-09-21 2006-05-23 Academia Sinica Mutant-type lipases and applications thereof
US6933288B2 (en) 2002-02-04 2005-08-23 Isis Pharmaceuticals, Inc. Pyranosyl cytosines: pharmaceutical formulations and methods
JP4348044B2 (ja) 2002-02-12 2009-10-21 株式会社キラルジェン 立体規則性の高いジヌクレオシドホスホロチオエートの製造法
WO2003106476A1 (fr) 2002-02-20 2003-12-24 Sirna Therapeutics, Inc Inhibition d'une infection a enterocoques et de l'activite de la cytolysine induite par des acides nucleiques
US8232383B2 (en) 2002-02-20 2012-07-31 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20050096284A1 (en) 2002-02-20 2005-05-05 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US7288376B2 (en) 2002-03-22 2007-10-30 Council Of Scientific And Industrial Research Method of detection of SP-A2 gene variants useful for prediction of predisposition to aspergillosis
US20040102394A1 (en) 2002-11-23 2004-05-27 Isis Pharmaceuticals Inc. Modulation of huntingtin interacting protein 2 expression
AU2003237875A1 (en) 2002-05-15 2003-12-02 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein b expression
AU2003237249A1 (en) 2002-05-24 2003-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
WO2003100017A2 (fr) 2002-05-24 2003-12-04 Isis Pharmaceuticals, Inc. Oligonucleotides a unites nucleosides modifiees
AU2003238772A1 (en) 2002-05-31 2003-12-19 Regents Of The University Of Minnesota In vitro evaluation of nucleic acid ligands
US7507808B2 (en) 2002-12-12 2009-03-24 Isis Pharmaceuticals, Inc. Modulation of endothelial lipase expression
WO2003106477A1 (fr) 2002-06-01 2003-12-24 Isis Pharmaceuticals, Inc. Composes oligomeres contenant des nucleosides carbocycliques et leur utilisation dans la modulation genique
JP4598519B2 (ja) 2002-06-20 2010-12-15 サイトス バイオテクノロジー アーゲー アジュバントとして使用するためのパッケージ化されたウィルス様粒子：調製法及び使用法
WO2004003228A1 (fr) 2002-07-01 2004-01-08 Unisearch Limited Methode de genotypage
EP1520022B1 (fr) 2002-07-10 2015-07-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interference de l'arn par des molecules d'arn simple brin
US20040023905A1 (en) 2002-07-31 2004-02-05 Isis Pharmaceuticals Inc. Antisense modulation of LAR expression
EP1386972A1 (fr) 2002-08-01 2004-02-04 Noxxon Pharma AG Procédé et dispositif pour la conception d'un acide nucléique avec une propriété désirable
US20050255086A1 (en) 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
US20050042646A1 (en) 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US8729036B2 (en) 2002-08-07 2014-05-20 University Of Massachusetts Compositions for RNA interference and methods of use thereof
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
US7414116B2 (en) 2002-08-23 2008-08-19 Illumina Cambridge Limited Labelled nucleotides
EP2330194A3 (fr) 2002-09-13 2011-10-12 Replicor, Inc. Oligonucléotides antiviraux non complémentaires de séquence
US7030230B2 (en) 2002-10-25 2006-04-18 Isis Pharmaceuticals, Inc. Process of purifying phosphoramidites
ZA200503511B (en) 2002-10-29 2006-10-25 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
AU2003295389A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. Conjugated oligomeric compounds and their use in gene modulation
AU2003291753B2 (en) 2002-11-05 2010-07-08 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
EP1560840B1 (fr) 2002-11-05 2015-05-06 Isis Pharmaceuticals, Inc. Compositions comprenant des nucleosides modifies en 2' de substitution destinees a la modulation de gene
WO2004044134A2 (fr) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Composes oligomeriques lies par phosphore et utilisation dans la modulation de gene
US7381527B2 (en) 2002-11-06 2008-06-03 Council Of Scientific And Industrial Research Method of detection of SP-A2 gene variants
WO2004044181A2 (fr) 2002-11-13 2004-05-27 Isis Pharmaceuticals, Inc. Modulation antisens de l'expression d'apolipoproteine b
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
EP2305813A3 (fr) 2002-11-14 2012-03-28 Dharmacon, Inc. SIRNA fonctionnel et hyperfonctionnel
EP2216407B1 (fr) 2003-03-07 2016-01-13 Alnylam Pharmaceuticals, Inc. Compositions thérapeutiques
GB0305422D0 (en) 2003-03-10 2003-04-16 Univ Open Detection, monitoring and treatment of cancer
WO2004083432A1 (fr) 2003-03-21 2004-09-30 Academisch Ziekenhuis Leiden Modulation de la reconnaissance d'exons dans le pre-arnm par interference avec la structure d'arn secondaire
GB0306657D0 (en) 2003-03-24 2003-04-30 Avecia Ltd Process and compounds
NZ542323A (en) 2003-03-26 2008-07-31 Cytos Biotechnology Ag Melan-A peptide analogue-virus-like-particle conjugates
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
WO2004094614A2 (fr) 2003-04-21 2004-11-04 Archemix Corp. Aptameres stabilises lies a un facteur de croissance derive de plaquette et leur utilisation en tant qu'agents therapeutiques d'oncologie
US7045306B2 (en) 2003-04-28 2006-05-16 The General Hospital Corporation Method for identifying compounds in vitro that modulate the dysregulation of transcription of transcription mediated by mutant huntingtin protein
US7214491B2 (en) 2003-05-07 2007-05-08 E. I. Du Pont De Nemours And Company Δ-12 desaturase gene suitable for altering levels of polyunsaturated fatty acids in oleaginous yeasts
AU2004239114B2 (en) 2003-05-14 2008-03-13 Japan Science And Technology Agency Inhibition of the expression of huntingtin gene
BRPI0410886A (pt) 2003-06-03 2006-07-04 Isis Pharmaceuticals Inc composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único
JP2007524615A (ja) 2003-06-20 2007-08-30 コーリー ファーマシューティカル ゲーエムベーハー 低分子トール様レセプター（ｔｌｒ）アンタゴニスト
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
JP2005089441A (ja) 2003-08-08 2005-04-07 Toudai Tlo Ltd 立体規則性の高いリン原子修飾ヌクレオチド類縁体の製造法
JP2011088935A (ja) 2003-08-08 2011-05-06 Chiralgen Ltd リン原子修飾ヌクレオチド類縁体の製造のための光学活性ヌクレオシド３’−ホスホロアミダイト
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
US7427672B2 (en) 2003-08-28 2008-09-23 Takeshi Imanishi Artificial nucleic acids of n-o bond crosslinkage type
JP4580870B2 (ja) 2003-09-02 2010-11-17 株式会社キラルジェン リボヌクレオチド又はリボヌクレオチド誘導体の製造方法
WO2005028494A1 (fr) 2003-09-02 2005-03-31 Takeshi Wada Procede de production d'un monomere 5'-phosphityle et d'un derive d'oligonucleotide h-phosphonate
US20050053981A1 (en) 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US20050074801A1 (en) 2003-09-09 2005-04-07 Monia Brett P. Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
BRPI0414222B8 (pt) 2003-09-09 2021-05-25 Geron Corp compostos oligonucleotídeos modificados para inibição da telomerase, métodos, composição farmacêutica e usos relacionados
WO2008005562A2 (fr) 2006-07-07 2008-01-10 University Of Massachusetts Compositions de silençage de l'arn, et méthodes de traitement de la chorée de huntington
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
EP2821085B1 (fr) 2003-09-12 2020-04-29 University of Massachusetts Interférence arn pour le traitement de troubles à gain
GB0323968D0 (en) 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
GEP20094767B (en) 2003-10-30 2009-09-10 Coley Pharm Group Inc C-class oligonucleotide analogs with enhanced immunostimulatory potency
WO2005042716A2 (fr) 2003-10-31 2005-05-12 President And Fellows Of Harvard College Oligonucleotides se liant a des acides nucleiques
US7846436B2 (en) 2003-11-28 2010-12-07 Chemgenes Corporation Oligonucleotides and related compounds
JP4945129B2 (ja) 2004-01-27 2012-06-06 株式会社キラルジェン フルオラス担体およびそれを用いたオリゴヌクレオチド誘導体の製造方法
US20050176045A1 (en) 2004-02-06 2005-08-11 Dharmacon, Inc. SNP discriminatory siRNA
WO2005076744A2 (fr) 2004-02-18 2005-08-25 Frutarom Ltd. Procede de preparation de conjugues peptides/oligonucleotides
JP3976742B2 (ja) 2004-02-27 2007-09-19 江守商事株式会社 インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
US20060193821A1 (en) 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
WO2005085272A1 (fr) 2004-03-05 2005-09-15 Takeshi Wada Monomere de boranophosphate et procede de production de derive oligonucleotide
WO2005092909A1 (fr) 2004-03-25 2005-10-06 Toudai Tlo, Ltd. Procédés de fabrication d'analogue ribonucléotide de forte stéréorégularité et analogue désoxyribonucléotide
US20050244869A1 (en) 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
WO2005097817A2 (fr) 2004-04-05 2005-10-20 Alnylam Pharmaceuticals, Inc. Procedes et reactifs pour la synthese et la purification d'oligonucleotides
WO2005113813A2 (fr) 2004-04-26 2005-12-01 Archemix Corporation Ligands d'acide nucleique specifiques de l'immunoglobuline et leur utilisation comme agents therapeutiques pour des maladies atopiques
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
EP1753881A2 (fr) 2004-05-27 2007-02-21 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Expression differentielle des molecules associees a un accident vasculaire cerebral aigu
US7759318B1 (en) 2004-05-28 2010-07-20 Isis Pharmaceuticals, Inc. Identification of novel pathways, genes and promoter motifs regulating adipogenesis
WO2005121372A2 (fr) 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Compositions a double brin comprenant des brins differentiellement modifies utilises dans la modulation genetique
EP3808845A1 (fr) 2004-06-28 2021-04-21 The University Of Western Australia Oligonucléotides antisens pour induire l'omission de l'exon et leurs procédés d'utilisation
AU2005272912A1 (en) * 2004-08-10 2006-02-23 Genzyme Corporation Antisense modulation of apolipoprotein B expression
MX2007002245A (es) 2004-08-26 2007-04-20 Nippon Shinyaku Co Ltd Compuesto de fosforamidita y metodo para la produccion de un acido oligorribonucleico.
JP2008512097A (ja) 2004-09-07 2008-04-24 アーケミックス コーポレイション アプタマー医薬品化学
BRPI0514984A (pt) 2004-09-07 2008-07-01 Archemix Corp aptámeros para o fator de von willebrand e sua utilização como terapêuticos para doença trombótica
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
WO2006031461A2 (fr) 2004-09-09 2006-03-23 Isis Pharmaceuticals, Inc. Groupes de pyrrolidinyle assurant la liaison de conjugues a des composes oligomeriques
WO2006034348A2 (fr) 2004-09-17 2006-03-30 Isis Pharmaceuticals, Inc. Oligonucleotides antisens ameliores
CA2582464A1 (fr) 2004-10-13 2006-04-27 Sanjay Bhanot Modulation antisens de l'expression de ptp1b
KR100721928B1 (ko) 2004-11-05 2007-05-28 주식회사 바이오씨에스 ＣｐＧ 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
EP1657307A1 (fr) 2004-11-16 2006-05-17 Immunotech S.A. Oligonucléotides induisant la sécrétion de GM-CSF
CA2589406A1 (fr) 2004-12-09 2006-06-15 Alnylam Pharmaceuticals, Inc. Compositions et methodes pour induire une reponse immunitaire chez un mammifere et methodes pour eviter une reponse immunitaire dirigee contre des agents oligonucleotidiques, notamment des arn interferents courts
WO2006065751A2 (fr) 2004-12-13 2006-06-22 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Promedicaments d'oligonucleotides cpg, compositions afferentes et procedes therapeutiques associes
WO2006066260A2 (fr) 2004-12-17 2006-06-22 Thiosense, Inc. Compositions de monomeres et oligomeres de phosphore chiraux et procedes de production
US20060183763A1 (en) 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
US20060166901A1 (en) 2005-01-03 2006-07-27 Yu Ruey J Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids
CN100485034C (zh) 2005-01-28 2009-05-06 权滢周 从分支杆菌中提取的用于刺激免疫功能，治疗免疫相关性疾病，过敏性皮炎和/或保护正常免疫细胞的寡核苷酸
AU2006216493A1 (en) 2005-02-24 2006-08-31 Coley Pharmaceutical Gmbh Immunostimulatory oligonucleotides
JP2006248949A (ja) * 2005-03-09 2006-09-21 Univ Nagoya ヌクレオシド誘導体、ヌクレオチド誘導体及びそれらの製造方法
JP5242375B2 (ja) 2005-04-01 2013-07-24 ザ レゲントス オブ ザ ユニバーシティ オブ カリフォルニア ホスホノ−ペント−２−エン−１−イルヌクレオシド及び類似体
ZA200709237B (en) 2005-05-05 2009-04-29 Antisense Pharma Gmbh Dosage of oligonucleotides
EP1885854B1 (fr) 2005-05-06 2012-10-17 Medtronic, Inc. Procedes et sequences permettant de supprimer l'expression du gene de huntington chez les primates
US7902352B2 (en) 2005-05-06 2011-03-08 Medtronic, Inc. Isolated nucleic acid duplex for reducing huntington gene expression
EP1896850A2 (fr) 2005-06-15 2008-03-12 The Ohio State University Research Foundation Aptamères qui se lient à une protéine de prion
US10242753B2 (en) 2005-06-17 2019-03-26 University Of Washington Method for measuring strength of associations of multidimensional traits
PL1910395T3 (pl) 2005-06-23 2013-03-29 Cold Spring Harbor Laboratory Kompozycja i sposób modulacji splicingu SMN2
ATE522626T1 (de) 2005-06-28 2011-09-15 Medtronic Inc Verfahren und nukleotid-sequenzen, die bevorzugt die expression eines mutierten huntingtin-genes unterdrücken
US9133517B2 (en) 2005-06-28 2015-09-15 Medtronics, Inc. Methods and sequences to preferentially suppress expression of mutated huntingtin
EP1948600B1 (fr) 2005-07-05 2014-04-16 The President & Fellows Of Harvard College Conjugues cibles sur le foie
JP4984634B2 (ja) 2005-07-21 2012-07-25 ソニー株式会社 物理情報取得方法および物理情報取得装置
ES2372538T3 (es) 2005-07-28 2012-01-23 Id-Fish Technology, Inc. Procedimiento para mejorar la permeabilidad celular a partículas foráneas.
MEP0208A (xx) 2005-08-26 2010-02-10 Archemix Corp Aptameri koji vezuje trombin sa visokim afininitetom
WO2007027775A2 (fr) 2005-08-29 2007-03-08 Isis Pharmaceuticals, Inc. Procedes a utiliser dans la modulation de mir-122a
WO2007028065A2 (fr) * 2005-08-30 2007-03-08 Isis Pharmaceuticals, Inc. Composes oligomeriques chimeriques pour la modulation de l'epissage
EP1931803A2 (fr) 2005-09-15 2008-06-18 Duke University Banques ciblees, profilage fonctionnel, laser selex et deselex
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070077993A1 (en) 2005-09-30 2007-04-05 Midgley Timothy M Method and apparatus for collecting user game play data and crediting users in a gaming environment
KR101455081B1 (ko) 2005-10-12 2014-10-27 이데라 파마슈티칼즈, 인코포레이티드 톨―유사 수용체 기초 면역 반응을 조절하기 위한 면역조절 올리고누클레오티드 (ｉｒｏ)
US9308252B2 (en) 2005-10-27 2016-04-12 Cook Biotech, Inc. Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
CN101365801B (zh) 2005-10-28 2013-03-27 阿尔尼拉姆医药品有限公司 抑制亨廷顿基因表达的组合物和方法
EP2471919A1 (fr) 2005-10-28 2012-07-04 Tosoh Corporation Procédé de préparation de micro-organisme de synthèse de caroténoïde et procédé de production des caroténoïdes
CA2628659A1 (fr) 2005-11-11 2007-05-24 Pfizer, Inc. Combinaisons et methodes d'utilisation d'un oligonucleotide immunomodulatoire
WO2007064291A1 (fr) 2005-11-30 2007-06-07 Jyoti Chattopadhyaya Procédé et composés permettant la synthèse de l'arn
EP1957507B1 (fr) 2005-12-02 2018-10-24 Ionis Pharmaceuticals, Inc. Analogues d'aminoglycoside 4,5-substitués antibactériens comportant plusieurs substituants
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
MEP0808A (xx) 2005-12-21 2010-02-10 Pfizer Prod Inc Karbonilamino pirolopirayoli, snažni inhibitori kinaza
PL2161038T3 (pl) 2006-01-26 2014-06-30 Ionis Pharmaceuticals Inc Kompozycje i ich zastosowanie ukierunkowane na huntingtynę
EP2314594B1 (fr) 2006-01-27 2014-07-23 Isis Pharmaceuticals, Inc. Analogues d'acide nucléique bicyclique modifiés en position 6
PL2135949T3 (pl) 2006-02-14 2013-03-29 Noxxon Pharma Ag Kwasy nukleinowe wiążące MCP-1
PT2405002E (pt) 2006-02-15 2015-01-05 Adiutide Pharmaceuticals Gmbh Composições e métodos para formulações de oligonucleotídeos
SI1991275T1 (sl) 2006-03-08 2015-03-31 Archemix Llc Komplement vezavni aptameri in sredstva proti C5, uporabni pri zdravljenju očesnih motenj
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
AU2007234451A1 (en) 2006-03-31 2007-10-11 Atom Acquisition, Llc Reagents useful for synthesizing rhodamine-labeled oligonucleotides
EP2010679A2 (fr) 2006-04-06 2009-01-07 Ibis Biosciences, Inc. Compositions pour l'identification de champignons
ATE476424T1 (de) 2006-04-20 2010-08-15 Hoffmann La Roche Diazepanderivate als modulatoren von chemokinrezeptoren
US8206923B2 (en) 2006-04-24 2012-06-26 Elvira Garza Gonzalez Method for detection and multiple, simultaneous quantification of pathogens by means of real-time polymerase chain reaction
WO2007127221A2 (fr) 2006-04-25 2007-11-08 Immune Disease Institute Inc. Administration ciblée vers des leucocytes au moyen de supports non protéiniques
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
WO2007143315A2 (fr) 2006-05-05 2007-12-13 Isis Pharmaceutical, Inc. Composés et procédés de modulation de l'expression de pcsk9
US8158598B2 (en) 2006-05-05 2012-04-17 Isis Pharmaceuticals, Inc. Compositions and their uses directed to PTPR alpha
US20090012120A1 (en) 2006-05-10 2009-01-08 Board Of Trustees Of Michigan State University Synthesis of N-heterocycles, beta-amino acids, and allyl amines via aza-payne mediated reaction of ylides and hydroxy aziridines
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
WO2007134181A2 (fr) 2006-05-11 2007-11-22 Isis Pharmaceuticals, Inc. Analogues d'acides nucléiques bicycliques modifiés en 5'
US20090048193A1 (en) 2006-05-26 2009-02-19 Rusconi Christopher P Administration of the REG1 anticoagulation system
WO2007139190A1 (fr) 2006-05-31 2007-12-06 Toray Industries, Inc. Oligonucléotide immunostimulant et son application pharmaceutique thereof
US8097596B2 (en) 2006-06-30 2012-01-17 Lakewood-Amedex, Inc. Compositions and methods for the treatment of muscle wasting
WO2008008884A2 (fr) 2006-07-12 2008-01-17 Cornell Research Foundation, Inc. Inhibition d'agrégation de peptide de bêta-amyloïde
WO2008008476A2 (fr) 2006-07-12 2008-01-17 The Regents Of The University Of California Distribution transductrice d'acides nucléiques par des groupes de protection phosphotriester réversible à neutralisation de charge
PT2041282T (pt) 2006-07-18 2018-03-13 Noxxon Pharma Ag Ácidos nucleicos que se ligam a fde-1
CN100503824C (zh) 2006-07-20 2009-06-24 武汉大学 抗结核杆菌感染的小分子核苷酸dna适配子及其制备方法
CA2659155A1 (fr) 2006-07-20 2008-01-24 Amgen Inc. Heterocycles aromatiques d'azole substitues, utilises en tant qu'inhibiteurs de ll~-hsd-1
AU2007281082A1 (en) 2006-08-04 2008-02-07 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of JNK proteins
AT504194B1 (de) 2006-09-07 2008-07-15 Oesterr Rotes Kreuz Bakteriennachweis
EP1897562A1 (fr) 2006-09-08 2008-03-12 Bayer Schering Pharma Aktiengesellschaft Aptaméres marquées avec Gallium-68
US8138330B2 (en) 2006-09-11 2012-03-20 Sigma-Aldrich Co. Llc Process for the synthesis of oligonucleotides
KR101251707B1 (ko) * 2006-09-27 2013-04-11 콜리 파마슈티칼 게엠베하 면역 자극 활성이 증강된 소수성 Ｔ 유사체를 함유하는 ＣｐＧ 올리고뉴클레오티드 유사체
DK2410053T4 (da) 2006-10-18 2020-08-31 Ionis Pharmaceuticals Inc Antisense-forbindelser
KR20090064463A (ko) 2006-10-23 2009-06-18 아이알엠 엘엘씨 카텝신 프로테아제 억제제
JP2010507386A (ja) 2006-10-26 2010-03-11 コーリー ファーマシューティカル ゲーエムベーハー オリゴリボヌクレオチドおよびその使用
FR2908414B1 (fr) 2006-11-13 2012-01-20 Centre Nat Rech Scient Immobilisation de proteines membranaires sur un support par l'intermediaire d'une molecule amphiphile
EP2099454A4 (fr) 2006-11-17 2010-11-10 Abbott Lab Aminopyrrolidines utilisés en tant qu'antagonistes du récepteur de la chimiokine
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
KR20090103894A (ko) 2006-11-27 2009-10-01 아이시스 파마수티컬즈 인코포레이티드 고콜레스테롤혈증을 치료하는 방법
KR100861108B1 (ko) 2006-11-28 2008-09-30 (주) 벡스코아 씨형 간염 바이러스 레플리콘 증식을 억제하는 알엔에이분해효소 저항성 알엔에이 압타머
CA2671883A1 (fr) 2006-12-12 2008-06-19 Idera Pharmaceuticals, Inc. Agonistes synthetiques du tlr9
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
US20100190837A1 (en) 2007-02-15 2010-07-29 Isis Pharmaceuticals, Inc. 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
CN101679979A (zh) 2007-03-24 2010-03-24 基酶有限公司 施用与人载脂蛋白b互补的反义寡核苷酸
US8399248B2 (en) * 2007-05-03 2013-03-19 Merck Sharp & Dohme Corp. Methods of using MIR34 as a biomarker for TP53 functional status
US7943591B2 (en) 2007-05-11 2011-05-17 Adynxx, Inc. Gene expression and pain
US20100285041A1 (en) * 2007-05-17 2010-11-11 Eugen Uhlmann Class A Oligonucleotides with Immunostimulatory Potency
US8222407B2 (en) 2007-05-24 2012-07-17 Kyorin Pharmaceutical Co., Ltd. Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position
GB0710186D0 (en) 2007-05-29 2007-07-04 Texas Instr Denmark PWM loop with minimum allasing error property
DK2170917T3 (da) 2007-05-30 2012-10-08 Isis Pharmaceuticals Inc N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro
CA2690091A1 (fr) 2007-06-05 2008-12-11 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Nouvelles phenylpyrrolidines disubstituees en tant que modulateurs de la neurotransmission catecholaminergique corticale
ES2386492T3 (es) 2007-06-08 2012-08-21 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos carbocíclicos
WO2008151833A2 (fr) 2007-06-13 2008-12-18 Hochschule Mannheim Composés pour la modulation de l'agrégation de l'huntingtine, procédés et moyens d'identification de tels composés
ATE462787T1 (de) 2007-06-18 2010-04-15 Commissariat Energie Atomique Reversibles sirna-silencing eines mutierten und endogenen huntington-wildtypgens und dessen anwendung zur behandlung von morbus huntington
CA2692579C (fr) 2007-07-05 2016-05-03 Isis Pharmaceuticals, Inc. Analogues d'acides nucleiques bicycliques disubstitues en position 6
EP2357231A2 (fr) 2007-07-09 2011-08-17 Idera Pharmaceuticals, Inc. Composés d'ARN modulatoire immunitaire stabilisé (SIMRA)
AU2008281281A1 (en) 2007-07-31 2009-02-05 University Of Saskatchewan Genetic variation in Pro-Melanin-Concentrating Hormone gene affects carcass traits in cattle
WO2009017803A2 (fr) 2007-08-02 2009-02-05 The Texas A & M University System Micro arn antisens et ses utilisations
JP2010536787A (ja) 2007-08-15 2010-12-02 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｏｌｌ様受容体モジュレータ
RU2501803C2 (ru) 2007-10-01 2013-12-20 Айзис Фармасьютикалз, Инк. Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4)
KR100886139B1 (ko) * 2007-11-13 2009-02-27 주식회사 삼천리제약 올리고뉴클레오타이드의 제조방법
PE20091669A1 (es) 2007-12-21 2009-12-06 Exelixis Inc Benzofuropirimidinonas
TWI340765B (en) 2007-12-26 2011-04-21 Ind Tech Res Inst Oligonucleotide sequences and dna chip for identifying filamentous microorganisms and the identification method thereof
WO2009089689A1 (fr) 2008-01-15 2009-07-23 Mediatek Inc. Système de présentation multimédia, appareil de traitement multimédia de celui-ci et procédé de présentation des signaux vidéo et audio
WO2009089659A1 (fr) 2008-01-18 2009-07-23 Shanghai Targetdrug Co., Ltd. Composés à base de pyrollidine
CA2711587A1 (fr) 2008-02-04 2009-08-13 Galapagos Nv Cibles et composes moleculaires, et procedes pour les identifier, destines au traitement de maladies neurodegeneratives
JP2009190983A (ja) 2008-02-12 2009-08-27 Tokyo Institute Of Technology オリゴヌクレオチド誘導体
US8426378B2 (en) 2008-03-21 2013-04-23 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising tricyclic nucelosides and methods for their use
WO2009142822A2 (fr) 2008-03-26 2009-11-26 Alnylam Pharmaceuticals, Inc. Agents d'interférence arn à modification 2-f
EP2271351A4 (fr) 2008-04-03 2016-08-31 Spring Bank Pharmaceuticals Inc Compositions et procédés pour traiter des infections virales
US9290534B2 (en) 2008-04-04 2016-03-22 Ionis Pharmaceuticals, Inc. Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
US8679750B2 (en) 2008-05-09 2014-03-25 The University Of British Columbia Methods and compositions for the treatment of Huntington'S disease
EP2297341A4 (fr) 2008-05-09 2013-01-09 Univ British Columbia Procédés et compositions pour le traitement de la maladie de huntington
WO2009143391A2 (fr) 2008-05-22 2009-11-26 Isis Pharmaceuticals, Inc Procédés de modulation de l’expression de creb
WO2009143390A2 (fr) 2008-05-22 2009-11-26 Isis Pharmaceuticals, Inc. Procédés de modulation de l’expression de rbp4
EP2294181A4 (fr) 2008-05-22 2013-04-24 Isis Pharmaceuticals Inc Modulation de l expression de smrt
WO2009148605A2 (fr) 2008-06-04 2009-12-10 Isis Pharmaceuticals, Inc. Procédés pour traiter une hypercholestérolémie
WO2010003133A2 (fr) 2008-07-03 2010-01-07 Exelixis Inc. Modulateurs de cdk
US8691971B2 (en) 2008-09-23 2014-04-08 Scott G. Petersen Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference
US8501805B2 (en) 2008-09-24 2013-08-06 Isis Pharmaceuticals, Inc. Substituted alpha-L-bicyclic nucleosides
US8604192B2 (en) 2008-09-24 2013-12-10 Isis Pharmaceuticals, Inc. Cyclohexenyl nucleic acids analogs
AU2009302385B2 (en) 2008-10-07 2015-12-03 President And Fellows Of Harvard College Telomerase inhibitors and methods of use thereof
AU2009308380B2 (en) 2008-10-22 2015-05-28 Suzhou Ribo Life Science Co., Ltd. Methods for treating eye disorders
AU2009308217B2 (en) 2008-10-24 2016-01-21 Ionis Pharmaceuticals, Inc. 5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
KR101881596B1 (ko) * 2008-12-02 2018-07-24 웨이브 라이프 사이언시스 재팬 인코포레이티드 인 원자 변형된 핵산의 합성 방법
EP2382227A1 (fr) 2008-12-23 2011-11-02 Girindus America, Inc. Réactifs de sulfurisation et leur utilisation pour la synthèse d'oligonucléotides
WO2010080953A1 (fr) 2009-01-08 2010-07-15 Isis Pharmaceuticals, Inc. Modèle de souris transgénique du métabolisme de la lipoprotéine humaine, de l'hypercholestérolémie et d'une maladie cardiovasculaire
WO2010091301A1 (fr) 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Composés oligomères et excipients
AU2010213795A1 (en) 2009-02-10 2011-08-04 Idera Pharmaceuticals, Inc. Synthetic RNA-based agonists of TLR7
AU2010221419B2 (en) 2009-03-02 2015-10-01 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
WO2010107838A1 (fr) 2009-03-16 2010-09-23 Isis Pharmaceuticals, Inc. Ciblage de l'apolipoprotéine b pour la réduction de l'apolipoprotéine c-iii
WO2010118263A1 (fr) 2009-04-08 2010-10-14 University Of Massachusetts Thérapies ciblant le polymorphisme nucléotidique (snp) destinées à traiter la maladie de huntington
WO2010120262A1 (fr) 2009-04-14 2010-10-21 Smith Holdings, Llc Méthodes et compositions pour le traitement d'états médicaux impliquant une programmation cellulaire
US9260493B2 (en) 2009-05-07 2016-02-16 The Regents Of The University Of California Transducible delivery of nucleic acids using modified dsRNA binding domains
AU2010256836A1 (en) 2009-06-01 2012-01-19 The Regents Of The University Of California Nucleic acid delivery compositions and methods of use thereof
EP3124491B1 (fr) 2009-06-05 2019-10-30 Infectious Disease Research Institute Adjuvants lipidiques synthétiques à base de glucopyranosyle et compositions de vaccin ainsi que compositions pharmaceutiques les contenant
MX361732B (es) 2009-06-17 2018-12-14 Cold Spring Harbor Laboratory Composiciones y metodos para la modulacion de division de smn2 en un sujeto.
CN102596204B (zh) 2009-07-06 2016-11-23 波涛生命科学有限公司 新的核酸前药及其使用方法
US8329024B2 (en) 2009-07-06 2012-12-11 Ada Technologies, Inc. Electrochemical device and method for long-term measurement of hypohalites
WO2011005860A2 (fr) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. Mimétiques de 5' phosphate
WO2011005942A2 (fr) 2009-07-08 2011-01-13 Idera Pharmaceuticals, Inc. Composés à base d'oligonucléotide en tant qu'inhibiteurs de récepteurs de type toll
WO2011015572A1 (fr) 2009-08-03 2011-02-10 Galapagos Nv Cibles et composés moléculaires, et procédés pour leur identification utiles dans le traitement de maladies neurodégénératives
WO2011015573A1 (fr) 2009-08-03 2011-02-10 Galapagos Nv Cibles et composés moléculaires, et procédés pour les identifier, utiles dans le traitement de maladies neurodégénératives
WO2011017521A2 (fr) 2009-08-06 2011-02-10 Isis Pharmaceuticals, Inc. Analogues d'acides nucléiques cyclohexoses bicycliques
US8927553B2 (en) 2009-08-10 2015-01-06 Daljit Singh Dhanoa Deuterium-enriched alkyl sulfonamides and uses thereof
CN102625809B (zh) 2009-09-11 2015-06-24 Isis制药公司 亨廷顿表达的调节
EP2479182B8 (fr) 2009-09-16 2016-07-13 Wave Life Sciences Japan, Inc. Nouveau groupe protecteur pour synthétiser de l'arn et dérivé de celui-ci
US20120270929A1 (en) 2009-09-25 2012-10-25 Isis Pharmaceuticals, Inc. Modulation of ttc39 expression to increase hdl
WO2011045702A1 (fr) 2009-10-15 2011-04-21 Pfizer Inc. Composés pyrrolo[2,3-d]pyrimidine
WO2011075560A1 (fr) 2009-12-17 2011-06-23 Merck Sharp & Dohme Corp. Aminopyrimidines en tant qu'inhibiteurs de la syk
WO2011080537A1 (fr) 2009-12-28 2011-07-07 Achira Labs Pvt. Ltd. Composition de gel de diagnostic, procédé de fabrication d'une composition de gel de diagnostic
AU2011203986C1 (en) 2010-01-08 2015-03-05 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
US8750507B2 (en) 2010-01-25 2014-06-10 Cisco Technology, Inc. Dynamic group creation for managed key servers
JP6006120B2 (ja) 2010-02-08 2016-10-12 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 対立遺伝子多様体の選択的低減
JP6018506B2 (ja) 2010-02-08 2016-11-02 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 対立遺伝子多様体の選択的低減
DK2534149T3 (da) 2010-02-10 2015-01-05 Glaxosmithkline Llc 6-amino-2-{ [ (1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-on-maleat
CN102918052A (zh) 2010-03-05 2013-02-06 国立大学法人东京大学 硫代磷酸核糖核苷的制造方法
WO2011127175A1 (fr) 2010-04-06 2011-10-13 Isis Pharmaceuticals, Inc. Modulation de l'expression de cd130 (gp130)
WO2011127307A1 (fr) 2010-04-07 2011-10-13 Isis Pharmaceuticals, Inc. Modulation de l'expression de cetp
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
EP2625186B1 (fr) 2010-04-28 2016-07-27 Ionis Pharmaceuticals, Inc. Nucléosides modifiés en 5' et composés oligomères préparés à partir de ceux-ci
CN103154014B (zh) 2010-04-28 2015-03-25 Isis制药公司 修饰核苷、其类似物以及由它们制备的寡聚化合物
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
GB201008902D0 (en) 2010-05-27 2010-07-14 Imp Innovations Ltd Membrane enhanced polymer sythesis
KR20130100278A (ko) 2010-08-31 2013-09-10 머크 샤프 앤드 돔 코포레이션 올리고뉴클레오티드의 전달을 위한 신규 단일 화학 존재물 및 방법
WO2012039448A1 (fr) 2010-09-24 2012-03-29 株式会社キラルジェン Groupe auxiliaire asymétrique
US9238812B2 (en) 2010-09-30 2016-01-19 Lsip, Llc Agent for suppressing expression of dominant mutant gene
KR101381048B1 (ko) 2010-10-20 2014-04-14 씨제이제일제당 (주) Ｏ-포스포세린 생산 균주 및 이로부터 생산된 ｏ-포스포세린으로부터 ｌ-시스테인 또는 이의 유도체의 생산방법
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
EP2633046A4 (fr) * 2010-10-29 2015-05-06 Alnylam Pharmaceuticals Inc Compositions et procédés pour inhiber des gènes pcsk9
EP3702460A1 (fr) 2010-11-12 2020-09-02 The General Hospital Corporation Arn non codants associés à polycomb
JP6093924B2 (ja) 2010-11-30 2017-03-15 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ ２’−ｏ−修飾ｒｎａ
EP2673361B1 (fr) 2011-02-08 2016-04-13 Ionis Pharmaceuticals, Inc. Composés oligomères comprenant des nucléotides bicycliques et leurs utilisations
EP2673286B1 (fr) 2011-02-12 2019-07-03 University of Iowa Research Foundation Composés thérapeutiques
US9353371B2 (en) 2011-05-02 2016-05-31 Ionis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with usher syndrome
FR2975600B1 (fr) 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris Agents pour le traitement de tumeurs
ES2626488T3 (es) 2011-07-19 2017-07-25 Wave Life Sciences Pte. Ltd. Procedimientos para la síntesis de ácidos nucleicos funcionalizados
DK2742135T4 (da) 2011-08-11 2020-07-13 Ionis Pharmaceuticals Inc Bindingsmodificerede gapped oligomeriske forbindelser og anvendelser deraf
US20140080896A1 (en) 2011-08-30 2014-03-20 The Regents Of The University Of California Identification of small molecules that facilitate therapeutic exon skipping
WO2013090457A2 (fr) 2011-12-12 2013-06-20 Oncoimmunin Inc. Administration in vivo d'oligonucléotides
CN102675386B (zh) 2011-12-24 2014-07-02 河南科技大学 一种龙胆苦苷分离提纯方法
WO2013134558A1 (fr) 2012-03-07 2013-09-12 The Texas A & M University System Traitement du cancer ciblant la surexpression d'arn non codant
KR20130114435A (ko) 2012-04-09 2013-10-17 삼성전자주식회사 다수의 전극을 갖는 생분자 검출 장치
IN2014DN10144A (fr) 2012-05-30 2015-08-21 Hokkaido System Science Co Ltd
SG11201500232UA (en) 2012-07-13 2015-04-29 Wave Life Sciences Pte Ltd Chiral control
EP2873674B1 (fr) 2012-07-13 2020-05-06 Shin Nippon Biomedical Laboratories, Ltd. Adjuvant d'acide nucléique chiral
AU2013288048A1 (en) 2012-07-13 2015-01-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
EP2879718B1 (fr) 2012-08-06 2023-06-07 Alnylam Pharmaceuticals, Inc. Procédés de préparation d'agents arn conjugués à des carbohydrates
CN104736551B (zh) 2012-08-15 2017-07-28 Ionis制药公司 使用改进的封端方案制备寡聚化合物的方法
WO2014059356A2 (fr) 2012-10-12 2014-04-17 Isis Pharmaceuticals, Inc. Composés anti-sens sélectifs et leurs utilisations
SG10201804331TA (en) 2012-11-15 2018-07-30 Roche Innovation Ct Copenhagen As Oligonucleotide conjugates
CA2889993A1 (fr) 2012-11-26 2014-05-30 Roche Innovation Center Copenhagen A/S Compositions et methodes pour la modulation de l'expression de fgfr3
AU2014211406B2 (en) 2013-01-30 2019-07-18 Roche Innovation Center Copenhagen A/S LNA oligonucleotide carbohydrate conjugates
WO2014118272A1 (fr) 2013-01-30 2014-08-07 Santaris Pharma A/S Conjugués glucidiques d'oligonucléotides antimir-22
EP3778618A1 (fr) 2013-02-04 2021-02-17 Ionis Pharmaceuticals, Inc. Composés antisens sélectifs et leurs utilisations
CN111593051A (zh) 2013-05-01 2020-08-28 Ionis制药公司 组合物和方法
KR20160013110A (ko) 2013-05-24 2016-02-03 로슈 이노베이션 센터 코펜하겐 에이/에스 B-세포 cll/림프종 11a(bcl11a)의 올리고뉴클레오티드 조절제 및 이의 용도
JP6477464B2 (ja) 2013-05-24 2019-03-06 味の素株式会社 モルフォリノオリゴヌクレオチドの製造方法
SI3013959T1 (sl) 2013-06-27 2020-04-30 Roche Innovation Center Copenhagen A/S Protismiselni oligomeri in konjugati, ki ciljajo PCSK9
TWI772856B (zh) 2013-07-19 2022-08-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
EP3024936B1 (fr) 2013-07-25 2019-09-04 Exicure, Inc. Constructions à partir d'acides nucléiques sphériques utilisées en tant qu'agents immunostimulants à des fins prophylactiques et thérapeutiques
EP3052521A1 (fr) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucléotides codant pour un récepteur de lipoprotéines de faible densité
US9988627B2 (en) 2013-10-04 2018-06-05 Novartis Ag Formats for organic compounds for use in RNA interference
CN105934524A (zh) 2013-11-11 2016-09-07 桑格摩生物科学股份有限公司 用于治疗亨廷顿氏病的方法和组合物
CN105722980A (zh) 2013-11-14 2016-06-29 罗氏创新中心哥本哈根有限公司 Apob反义缀合物化合物
US20150167017A1 (en) 2013-12-13 2015-06-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
EP3095461A4 (fr) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Adjuvant d'acide nucléique chiral possédant une activité d'induction d'immunité, et activateur d'induction d'immunité
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
EP3095459A4 (fr) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Adjuvant d'acide nucléique chiral ayant un effet antitumoral et agent antitumoral
CN106068325B (zh) 2014-01-16 2021-07-09 波涛生命科学有限公司 手性设计
EP3647318B1 (fr) 2014-04-28 2021-06-30 Ionis Pharmaceuticals, Inc. Composés oligomères modifiés de liaison
EP3137605B1 (fr) 2014-05-01 2020-10-28 Ionis Pharmaceuticals, Inc. Compositions et méthodes de modulation de l'expression de l'angiopoïétine de type 3
RU2691102C2 (ru) 2014-05-08 2019-06-11 Сангамо Байосайенсиз, Инк. Способы и композиции для лечения болезни хантингтона
WO2015179525A1 (fr) 2014-05-20 2015-11-26 University Of Iowa Research Foundation Composés thérapeutiques pour la maladie de huntington
US20160017327A1 (en) 2014-07-11 2016-01-21 The Johns Hopkins University Phosphorodiamidate morpholino oligomers (pmos) and their use in suppression of mutant huntingtin expression and attenuation of neurotoxicity
WO2016011226A1 (fr) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Polynucléotides chimériques
EP2982758A1 (fr) 2014-08-04 2016-02-10 Centre Hospitalier Universitaire Vaudois (CHUV) Édition de génome pour le traitement de la maladie de Huntington
WO2016027168A2 (fr) 2014-08-20 2016-02-25 Lifesplice Pharma Llc Oligonucléotides modulateurs d'épissage et leurs procédés d'utilisation
SG10201903290YA (en) 2014-08-20 2019-05-30 Alnylam Pharmaceuticals Inc Modified double-stranded rna agents
WO2016037191A1 (fr) 2014-09-05 2016-03-10 Health Research, Inc. Utilisation de plasmides et peptides dérivés de l'huntingtine pour une immunisation active comme agent thérapeutique de la maladie de huntington (hd)
US20180016575A1 (en) 2014-11-19 2018-01-18 Roche Innovation Center Copenhagen A/S LNA Gapmer Oligonucleotides Comprising Chiral Phosphorothioate Linkages
JP6689279B2 (ja) 2014-12-16 2020-05-20 ロシュ イノベーション センター コペンハーゲン エーエス キラル毒性のスクリーニング方法
MX2017008500A (es) 2014-12-24 2018-02-01 Uniqure Ip Bv Supresión del gen de la huntingtina inducida por la arni.
US9688707B2 (en) 2014-12-30 2017-06-27 Ionis Pharmaceuticals, Inc. Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
EP3253871A1 (fr) 2015-02-04 2017-12-13 Bristol-Myers Squibb Company Oligonucléotides lna à flancs alternés
US11761951B2 (en) 2015-02-04 2023-09-19 Bristol-Myers Squibb Company Methods of selecting therapeutic molecules
MX2017010369A (es) 2015-02-10 2017-12-14 Genzyme Corp Arni variante.
JP2018510621A (ja) 2015-02-13 2018-04-19 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． パタチン様ホスホリパーゼドメイン含有３（ＰＮＰＬＡ３）ｉＲＮＡ組成物およびその使用方法
EP3262174A4 (fr) 2015-02-23 2018-10-17 Ionis Pharmaceuticals, Inc. Composés et procédés pour augmenter l'activité antisens
EP3265098A4 (fr) 2015-03-03 2019-02-13 Ionis Pharmaceuticals, Inc. Compositions permettant de moduler l'expression de mecp2
WO2016154096A1 (fr) 2015-03-20 2016-09-29 Ionis Pharmaceuticals, Inc. Modulation de l'expression de smggds
LT3277814T (lt) 2015-04-03 2020-10-26 University Of Massachusetts Oligonukleotidų junginiai, skirti nukreipimui į hantingtino mrnr
US10851371B2 (en) 2015-04-10 2020-12-01 Ionis Pharmaceuticals, Inc. Modulation of SMN expression
WO2016167780A1 (fr) 2015-04-16 2016-10-20 Ionis Pharmaceuticals, Inc. Compositions destinées à moduler l'expression du transcrit antisens c9orf72
WO2016209862A1 (fr) 2015-06-23 2016-12-29 Alnylam Pharmaceuticals, Inc. Compositions d'arndb contre un gène de glucokinase (gck) et leurs procédés d'utilisation
EP3313989A4 (fr) 2015-06-29 2018-12-05 Ionis Pharmaceuticals, Inc. Arn crispr modifié et arn crispr simple modifié et utilisations correspondantes
AU2016294347B2 (en) 2015-07-10 2022-07-28 Ionis Pharmaceuticals, Inc. Modulators of diacyglycerol acyltransferase 2 (DGAT2)
US10494632B2 (en) 2015-07-10 2019-12-03 Alnylam Pharmaceuticals, Inc. Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
CA2989970A1 (fr) 2015-07-17 2017-01-26 Alnylam Pharmaceuticals, Inc. Conjugues constitues d'une entite unique a cibles multiples
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
WO2017019660A1 (fr) 2015-07-27 2017-02-02 Alnylam Pharmaceuticals, Inc. Compositions d'arni de xanthine déshydrogénase et leurs méthodes d'utilisation
SI3329002T1 (sl) 2015-07-31 2021-02-26 Alnylam Pharmaceuticals, Inc. Sestavki transtiretin (TTR) IRNA in sestavki in postopki njihove uporabe za zdravljenje ali preprečevanje s TTR povezanih bolezni
EP3341479B1 (fr) 2015-08-24 2019-12-18 Roche Innovation Center Copenhagen A/S Procédé lna-g
WO2017035340A1 (fr) 2015-08-25 2017-03-02 Alnylam Pharmaceuticals, Inc. Procédés et compositions pour le traitement d'un trouble associé à un gène de proprotéine convertase subtilisine kexine (pcsk9)
PE20181131A1 (es) 2015-09-02 2018-07-17 Alnylam Pharmaceuticals Inc COMPOSICIONES DE ARNi PARA LIGANDO 1 DE MUERTE CELULAR PROGRAMADA 1 (PD-L1) Y METODOS DE USO DE LAS MISMAS
WO2017055423A1 (fr) 2015-10-02 2017-04-06 Roche Innovation Center Copenhagen A/S Procédé de conjugaison d'oligonucléotides
IL295755A (en) 2015-10-09 2022-10-01 Wave Life Sciences Ltd Oligonucleotide preparations and methods thereof
WO2017068087A1 (fr) 2015-10-22 2017-04-27 Roche Innovation Center Copenhagen A/S Procédé de détection d'oligonucléotides
WO2017067970A1 (fr) 2015-10-22 2017-04-27 Roche Innovation Center Copenhagen A/S Essai de dépistage de la toxicité in vitro
CN108350431A (zh) 2015-11-12 2018-07-31 豪夫迈·罗氏有限公司 用于确定候选药物的功效特征的方法
EP3430019A4 (fr) 2016-03-13 2019-10-30 Wave Life Sciences Ltd. Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides
AR108038A1 (es) 2016-03-14 2018-07-11 Roche Innovation Ct Copenhagen As Oligonucleótidos para reducir la expresión de pd-l1 (ligando de muerte programada-1)
JP7017517B2 (ja) 2016-03-18 2022-02-08 ロシュ イノベーション センター コペンハーゲン エーエス アシル保護ｌ－ｌｎａ－グアノシンモノマー
CN109153697A (zh) 2016-04-14 2019-01-04 豪夫迈·罗氏有限公司 三苯甲基-单-GalNAc化合物及其用途
MA45290A (fr) 2016-05-04 2019-03-13 Wave Life Sciences Ltd Procédés et compositions d'agents biologiquement actifs
MA45270A (fr) 2016-05-04 2017-11-09 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
US11261209B2 (en) 2016-05-12 2022-03-01 Roche Innovation Center Copenhagen A/S Enhanced coupling of stereodefined oxazaphospholidine phosphoramidite monomers to nucleoside or oligonucleotide
ES2954252T3 (es) 2016-05-13 2023-11-21 Hoffmann La Roche Matrices y dispositivos de recogida de muestras basados en proteínas
EP3463386A4 (fr) 2016-06-03 2020-03-04 Wave Life Sciences Ltd. Oligonucléotides, compositions et méthodes associées
WO2018022473A1 (fr) 2016-07-25 2018-02-01 Wave Life Sciences Ltd. Phasage
US11873316B2 (en) 2016-11-23 2024-01-16 Wave Life Sciences Ltd. Compositions and methods for phosphoramidite and oligonucleotide synthesis
US11603532B2 (en) 2017-06-02 2023-03-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
EP3630788A4 (fr) 2017-06-02 2021-04-28 Wave Life Sciences Ltd. Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3630789A4 (fr) 2017-06-02 2021-06-16 Wave Life Sciences Ltd. Compositions d'oligonucléotides et leurs procédés d'utilisation
CN111051281A (zh) 2017-06-21 2020-04-21 波涛生命科学有限公司 用于合成的化合物、组合物和方法
CN110831951B (zh) 2017-06-28 2023-10-27 罗氏创新中心哥本哈根有限公司 多重偶联和氧化方法
US20200362337A1 (en) 2017-08-08 2020-11-19 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
AU2018333065B2 (en) 2017-09-18 2024-04-18 Wave Life Sciences Ltd. Technologies for oligonucleotide preparation
US11596646B2 (en) 2017-10-12 2023-03-07 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
EP3728281A1 (fr) 2017-12-21 2020-10-28 Alnylam Pharmaceuticals Inc. Agents d'arn double brin à enrichissement chiral
IL277889B1 (en) 2018-04-12 2024-09-01 Wave Life Sciences Ltd Preparations of oligonucleotides and methods of using them
CA3098624A1 (fr) 2018-05-11 2019-11-14 Wave Life Sciences Ltd. Compositions d'oligonucleotides et leurs procedes d'utilisation
AU2019392928A1 (en) 2018-12-06 2021-06-17 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
CN113423385A (zh) 2019-02-01 2021-09-21 波涛生命科学有限公司 寡核苷酸组合物及其方法
FR3093595B1 (fr) 2019-03-07 2022-03-11 Thales Sa Systeme de calibration depuis le sol d'une charge utile d'un satellite
WO2020191252A1 (fr) 2019-03-20 2020-09-24 Wave Life Sciences Ltd. Technologies utiles pour la préparation d'oligonucléotides
US20220307019A1 (en) 2019-03-25 2022-09-29 National University Corporation Tokyo Medical And Dental University Double-stranded nucleic acid complex and use thereof
WO2020219983A2 (fr) 2019-04-25 2020-10-29 Wave Life Sciences Ltd. Compositions d'oligonucléotides et leurs méthodes d'utilisation
CA3137740A1 (fr) 2019-04-25 2020-10-29 Wave Life Sciences Ltd. Compositions d'oligonucleotides et leurs procedes d'utilisation
JP2022532169A (ja) 2019-05-09 2022-07-13 ウェイブ ライフ サイエンシズ リミテッド オリゴヌクレオチド組成物及びその使用方法
KR20220076508A (ko) 2019-10-06 2022-06-08 웨이브 라이프 사이언시스 리미티드 올리고뉴클레오티드 조성물 및 이의 사용 방법
AU2020363344A1 (en) 2019-10-06 2022-05-26 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2021178237A2 (fr) 2020-03-01 2021-09-10 Wave Life Sciences Ltd. Compositions oligonucléotidiques et méthodes associées
US20230203087A1 (en) 2020-05-22 2023-06-29 Pachamuthu Kandasamy Oligonucleotide compositions and methods thereof

Also Published As

Publication number Publication date
JP2022050518A (ja) 2022-03-30
PL2872147T3 (pl) 2023-09-25
JP2015528002A (ja) 2015-09-24
RU2015104762A (ru) 2018-08-31
EP4219516A3 (fr) 2024-01-10
AU2018205183A1 (en) 2018-08-02
KR20240148947A (ko) 2024-10-11
IL236621A0 (en) 2015-02-26
KR102450907B1 (ko) 2022-10-04
EP4219516A2 (fr) 2023-08-02
CN112007045A (zh) 2020-12-01
KR20220139425A (ko) 2022-10-14
AU2013289880B2 (en) 2018-08-02
WO2014012081A2 (fr) 2014-01-16
JP7004637B2 (ja) 2022-02-04
US9982257B2 (en) 2018-05-29
AU2020244546B2 (en) 2022-09-22
AU2013289880A1 (en) 2015-02-05
CN104661664A (zh) 2015-05-27
CA2878945A1 (fr) 2014-01-16
CL2015000092A1 (es) 2015-08-07
US20170275621A1 (en) 2017-09-28
AU2022291426A1 (en) 2023-02-02
US20240229026A1 (en) 2024-07-11
ES2940887T3 (es) 2023-05-12
EP2872147B1 (fr) 2022-12-21
CN104661664B (zh) 2020-07-03
US20150211006A1 (en) 2015-07-30
EP2872147A2 (fr) 2015-05-20
KR102213609B1 (ko) 2021-02-08
AU2020244546A1 (en) 2020-10-29
IL236621B (en) 2019-12-31
US10590413B2 (en) 2020-03-17
KR20150036642A (ko) 2015-04-07
DK2872147T3 (da) 2023-02-20
EP2872147A4 (fr) 2016-01-20
HK1210595A1 (en) 2016-04-29
SG10201700283WA (en) 2017-03-30
US11643657B2 (en) 2023-05-09
AU2018205183B2 (en) 2020-07-02
KR20210016078A (ko) 2021-02-10
SG10201912895PA (en) 2020-02-27
RU2015104762A3 (fr) 2018-08-31
WO2014012081A3 (fr) 2014-03-06
KR102712879B1 (ko) 2024-10-04
US20210130821A1 (en) 2021-05-06
MX2015000577A (es) 2015-08-14
JP6453212B2 (ja) 2019-01-16
JP2019069971A (ja) 2019-05-09

Similar Documents

Publication Publication Date Title
HK1210595A1 (en) Chiral control
EP2930595A4 (fr) Interface de commande de système de gestion d'installation
GB2500583B (en) Interference control
EP2925646A4 (fr) Commande d'accumulateur
EP2834259A4 (fr) Polynucléotides modifiés
EP2925647A4 (fr) Gestion d'accumulation
GB201221069D0 (en) Control method
GB2522151B (en) Component temperature control
GB2507584B (en) Control circuitry
HK1212128A1 (en) Rendering time control
IL235613B (en) Print head control
EP2811284A4 (fr) Unité de commande
GB201215667D0 (en) Control assembly
PT2802488T (pt) Comando de limpa pára-brisas
PL2636959T3 (pl) Regulacja korpusu grzejnego
PL2674683T3 (pl) Sterowanie instalacją grzewczą
GB201300597D0 (en) Clearance control
GB2518990B (en) Controls
GB2505396B (en) Flow control
GB201210472D0 (en) Obtaining control words
GB201119829D0 (en) Showwer control
HK1206749A1 (en) Modified polynucleotides
GB201218924D0 (en) Clearance control
AU342207S (en) Jewelley setting
SI2703248T1 (sl) Krmiljenje nagiba